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Résumé 
 L'interleukine-15 (IL-15) contribue au développement et à l’activation des 
lymphocytes T CD8, des cellules immunes qui ont été  impliquées dans plusieurs maladies 
auto-immunes telle la sclérose en plaques. Des niveaux élevés de l'IL-15 ont été trouvés 
chez les patients atteints de cette maladie comparativement aux témoins, mais aucune 
étude n'a examiné les effets de tels niveaux élevés sur les lymphocytes T CD8. Les 
objectifs de notre étude étaient 1- de caractériser l’expression de l'IL-15 par des 
lymphocytes B humains et de déterminer ses effets sur les fonctions des lymphocytes T 
CD8, et 2- d’évaluer l'expression in vivo de l'IL-15 dans des modèles murins de la sclérose 
en plaques. 
 Nous avons établi que les cellules B humaines augmentaient leur expression de  
l'IL-15 suite à une stimulation via le CD40. De plus, les fonctions effectrices des 
lymphocytes T CD8 ont été significativement augmentées lors des co-cultures avec des 
cellules B alloréactives exprimant l'IL-15. Dans les modèles murins de la sclérose en 
plaques, nous avons détecté au sein du système nerveux central des cellules immunes 
exprimant l’IL-15 ainsi que des cellules T CD8 exprimant le récepteur pour cette cytokine 
à différents stades de la maladie.  
 Nous avons démontré que les cellules B modulent des réponses des lymphocytes T 
CD8 via l’IL-15, ce qui suggère un rôle pour les cellules B dans la pathogenèse de la 
sclérose en plaques. Nous avons aussi mis en évidence la présence de cellules exprimant 
l’IL-15 dans le système nerveux central dans des modèles murins de cette maladie. 
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Summary 
 
 Interleukin-15 is a cytokine involved in the homeostatic proliferation and 
maintenance of CD8 T cells. Activated CD8 T cells are implicated in several autoimmune 
diseases, including Multiple Sclerosis (MS). Elevated levels of IL-15 have been reported in 
serum and on peripheral leukocytes of MS patients relative to controls, yet no study has 
addressed the effects of elevated IL-15 levels on CD8 T cells. To study the in vivo effects 
of any molecule, the animal model for MS, EAE, is used; the expression of IL-15 during 
the EAE disease course has not yet been elucidated. Thus the goals of our study were to 
characterize surface IL-15 expression on human B lymphocytes and determine the effects 
on human CD8 T cell functions; and to assess the in vivo expression of IL-15 in MS mouse 
models. 
 We found that B cells are capable of up-regulating the expression of surface IL-15 
upon CD40 stimulation, and CD8 T cell effector functions were significantly enhanced 
upon co-culture with alloreactive IL-15-expressing B cells. In the MS mouse models we 
used, we found IL-15-expressing immune cells present within the central nervous system 
(CNS) at various points of disease, and that CNS-infiltrating CD8 T cells were potentially 
responsive to IL-15.  
 Here, we not only demonstrate the modulation of CD8 T cell responses by IL-15 
presented by B cells, implying a role for B cells in MS pathogenesis, but also show the 
presence of IL-15-expressing cells within the inflamed CNS of EAE. 
 
Key Words 
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1.0. THE IMMUNE SYSTEM 
 The immune system is divided into two main branches: the innate immune system 
which serves as the first line of defense, and the adaptive immune system which tailors 
specific responses to and develops memory against pathogens. While there are two arms of 
the immune system defined, they usually act together: the activation of an antigen-specific 
response is initiated by components of the innate system, and the adaptive response will 
include innate effector responses to aid in promoting pathogen clearance. Thus, the 
cooperative effect of the two aspects of the immune system is necessary for a complete and 
effective immune response. 
 The innate immune system has various and diverse elements: there are physical 
barriers preventing the entry of pathogens into the body, from the epithelial cell layers with 
tight cell-cell contacts, to the mucus layers covering the respiratory and gastrointestinal 
tracts. It also includes various proteins and compounds or molecules produced by the 
innate system cells, including complement and chemokines and cytokines which attract 
and regulate the function of other immune cells. Lastly, the cells of the innate system 
express a range of pattern recognition receptors (PRRs), giving it the ability to respond to a 
number of pathogen-associated molecular patterns (PAMPs) on pathogens. Among the 
PRRs are Toll-like Receptors (TLRs) which recognize PAMPs such as lipopolysaccharide 
(LPS) from Gram negative bacteria, viral double-stranded RNA and unmethylated DNA 
with CpG motifs. Among the cells comprising the innate system, are natural killer cells, 
macrophages and dendritic cells (DC). The latter two cell types are phagocytic and, 
together with B cells, are classified as professional antigen presenting cells (APC). After 
processing of internalized proteins, these cells can present various antigens (Ag) to other 
immune cells on Major Histocompatibility Complex (MHC) Class II. DC, as well as 
activated B cells, have the ability to cross-present antigen on MHC Class I molecules as 
well. The efficacy of the first line of defense, namely the innate immune response, in 
addition to other factors, will contribute to whether or not the adaptive response is 
initiated.  
 The adaptive immune response is largely dependent on the receptors expressed on 
the T or B cell surface. The varied repertoire is due to the re-arrangement of the genes 
encoding the receptors; this resulting receptor diversity confers the ability of the adaptive 
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system to specifically respond to pathogenic insult, and to generate immune memory. The 
response of the adaptive system can be classified under two categories: the humoral 
response mediated by B cells, and the cell-mediated response mediated by T cells. In the 
former case, upon activation via the B cell receptor (BCR), these cells will secrete 
antibodies which promote opsonization and phagocytosis of foreign matter. Cellular 
immunity involves the activation of T cells via the T cell receptor (TCR) which occurs via 
recognition of antigen presented by MHC in addition to a co-stimulatory signal. Activation 
of the immune system will result in a strong and targeted response to allow pathogenic 
clearance including killing of pathogen-bearing cells; thus it is important that a balance is 
maintained with respect to the activation status of the immune cells, and that they do not 
become “mis”-activated.  
 
1.1 Adaptive immunity: Cell-mediated response 
1.1.1 T cell development 
 It is well-established that the thymus is crucial in providing the support T cell 
progenitors require for development, differentiation and selection to occur (Miller, 2002; 
Petrie, 2002). Progenitors, upon entering the thymus, are influenced by various factors; 
early expansion is influenced by IL-7, an essential factor in T cell development, (von 
Freeden-Jeffry et al., 1995), accompanied by the induction of various transcription factors, 
such as Notch (Zuniga-Pflucker, 2004) which serve to commit the precursor cells to the T 
cell lineage and induce expression of the genes required for TCR assembly. 
 The genes encoding TCRs are in a non-functional state; they exist as arrays of 
variable (V), diversity (D; present in only the β and δ chains of the TCR) and joining (J) 
segments; rearrangement is required for the creation of the genes encoding for the α and β 
or γ and δ chains of the TCR. Rearrangements are mediated by a protein complex encoded 
by recombinase-activating genes 1 and 2 (RAG). RAG binds and cleaves the DNA at 
specific sites flanking the V, D and J segments; the DNA ends are repaired and the 
resulting recombination, if functional, dictates the final structure and binding specificity of 
the TCR (Schatz and Ji, 2011). T cells expressing the αβ TCR will become double-
positive, expressing both CD4 and CD8 (co-receptors of the TCR). The subsequent 
selection of T cells is crucial. Cells with TCRs that do not recognize or bind to self-MHC 
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molecules with low avidity are eliminated (positive selection), as are those with TCRs that 
recognize self-peptides presented by MHC molecules with too high avidity (negative 
selection) (Takahama, 2006), ensuring that self-reactive T cells do not mature. Self-
reactive T cells escaping such selection can result in the development of autoimmune 
disease. 
 
1.1.2 The TCR complex and co-receptors 
 The TCR is a heterodimer of di-sulfide linked α and β or γ and δ chains, and forms 
a complex together with CD3. CD3 is made up of the invariant proteins of the CD3 family 
(γ, δ and ε) and the ζ family (Clevers et al., 1988; Fernandez-Miguel et al., 1999). The 
CD3 chains possess sequence motifs for tyrosine phosphorylation, known as ITAMs 
(immunoreceptor tyrosine-based activation motif) (Davis, 2002); it is the CD3 component 
of the complex which is responsible for signaling upon stimulation of the TCR (Fernandez-
Miguel et al., 1999). There are two pathways, it seems, which trigger T cell activation 
upon TCR stimulation: the first is tyrosine phosphorylation of the ζ chain ITAMs by src 
kinases (Salmond et al., 2009), and the second involves a conformational change in the 
CD3ε chain leading to Nck (an adaptor protein) recruitment (Davis, 2002). In either case, 
engagement of the TCR leads to the subsequent signaling via CD3, resulting in T cell 
activation; however, before signaling even occurs, the TCR needs to recognize and bind to 
a MHC-peptide complex. Aiding this process, the TCR/CD3 complex is further associated 
with other molecules, which further confer a degree of specificity to the T cell.  
 CD4 and CD8 are co-receptors to the TCR; they are trans-membrane glycoproteins, 
each with immunoglobulin-like (Ig-like) extracellular domains, and a short cytoplasmic tail 
(Leahy, 1995; Littman, 1987) which interacts with lck (Leahy, 1995), a src-family kinase, 
and thus they also play a role in signaling. There still are, however, differences in their 
structures. CD4 is a monomer with four Ig-like domains, and CD8 exists as a dimmer of 
either two α chains or an α and β chain (Leahy, 1995). These co-receptors play a role in 
MHC recognition by the TCR complex, increasing the affinity and stabilizing the 
interaction; CD4 and CD8 bind to non-polymorphic regions (von Freeden-Jeffry et al., 
1995) of MHC class II or MHC class I respectively.  
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 Stimulation of the TCR, while necessary, is not sufficient to fully induce a T cell 
response. Co-stimulation whether positive or negative, is also required. There are various 
co-stimulatory molecules, some of which are constitutively expressed and others which are 
induced. Among the co-stimulatory molecules expressed on T cells, are CD28, ICOS, 
CD30, 4-1BB, which result in positive signaling, and BTLA, CTLA-4 (CD152) and PD-1 
regulators, which dampen activation of T cells (Beier et al., 2007).  CD28 is constitutively 
expressed on T cells, and interacts with CD80/CD86 on APCs. In conjunction with TCR 
stimulation, CD28 ligation promotes IL-4 and IL-5 production, and induces increased 
levels of IL-2, which enhances proliferation in an autocrine manner and induces resistance 
to apoptosis (Beier et al., 2007).  
 
1.1.3 T cell effectors 
 The effector functions of T cells are diverse and varied: they can function as helper 
cells by providing various signals to enhance responses mediated by several other immune 
cells; they may be directly involved in eliminating pathogens by killing infected cells, and 
T cells can also regulate and dampen immune responses, limiting tissue damage.  
 
1.1.3.1 CD4 T cells 
 Naïve CD4 T cells (Th cells) differentiate into various helper T cell subsets upon 
activation. After stimulation by APCs, Th cells begin to produce IL-2; as they continue to 
respond to activating signals, they further differentiate (Chaplin, 2010). Th1 and Th2 are 
the classical helper cell subtypes; a specialized subset is the follicular helper cells. 
Regulatory T cells (Tregs) and recently, Th17 (Steinman, 2007) and Th9 (Veldhoen et al., 
2008) cells have also been described. 
 Th1 cells drive cell-mediated responses, via activation of mononuclear phagocytes, 
natural killer cells and cytolytic T cells, licensing them to kill cells infected with 
intracellular pathogens. They produce IFNγ and IL-2, as well as lymphotoxin (Bonilla and 
Oettgen, 2010; Chaplin, 2010). Naïve helper CD4 T cells differentiate into Th1 cells under 
the influence of IL-12, IFNγ and the T-box expressed in T cell (T-bet) transcription factor 
(Bonilla and Oettgen, 2010).  
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 Th2 cells differentiate under the influence of IL-4 and the transcription factor 
GATA-3 (Bonilla and Oettgen, 2010). They produce IL-4, 5, 10, and 13 and are 
responsible for enhancing antibody production by B cells, promoting clearance of parasites 
and extracellular pathogens.  
 Follicular helper cells are memory CD4 T cells which trigger the activation of B 
cells and reside in the lymph nodes and spleen; they express CXCR5, which mediates their 
recruitment to follicles (Bonilla and Oettgen, 2010). Th17 cells are induced in response to 
extracellular bacteria, and serve to help recruit neutrophils (Chaplin, 2010); this cell subset 
is also thought to play a role in autoimmunity (Bonilla and Oettgen, 2010). Th17 cell 
differentiation is induced by IL-1, IL-6 and TGF-β (Chung et al., 2009), in addition to 
autocrine IL-21 (Korn et al., 2009) under the direction of the transcription factors RORγt 
and RORα (Yang et al., 2008). IL-23 is also required for the expansion and maintenance of 
these cells (McGeachy et al., 2009), and differentiation is prevented by IL-12 and IFNγ 
(Harrington et al., 2005). Th17 cells produce IL-17 (A-F), a strong proinflammatory 
cytokine (Harrington et al., 2005; Korn et al., 2009; Steinman, 2007), as well as IL-6, GM-
CSF and TNFα. Via their cytokine profile, Th17 cells are able to suppress regulatory T 
cells (Pasare and Medzhitov, 2003), stimulate macrophage differentiation (Hamilton and 
Anderson, 2004) and induce apoptosis (Hehlgans and Pfeffer, 2005).  
 
1.1.3.2 CD8 T cells 
 CD8 T cells destroy infected cells or transformed cells; they are MHC class I 
restricted, and thus recognize antigens derived from polypeptides present in the cytosol. 
Upon activation, naïve CD8 T cells differentiate into cytotoxic T lymphocytes (CTLs) and 
are capable of killing target cells, in a contact-dependent manner. However it must be 
noted that CD8 T cells have functions other than killing; they produce cytokines such as 
IFNg and TNF as well as chemokines which recruit and or activate macrophages, 
neutrophils and microbicidal effector cells (Harty and Bevan, 1999; Harty et al., 2000) and 
which may also have the effect of interfering with pathogen attachment or gene expression 
(Harty et al., 2000). 
 The generation of effector CTL requires multiple signals; the signaling cascades of 
these events have been extensively studied in mouse models of viral infections. The first of 
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these is the interaction between the TCR and MHC class I molecules presenting Ag. A co-
stimulatory signal is required for the full activation of a CD8 T cell. The “typical” co-
stimulation of CD8 T cells is the interaction between CD80 or CD86 (members of the B7 
family) and CD28, which results in IL-2 production (Lenschow et al., 1996; Sharpe and 
Freeman, 2002). Another co-stimulatory molecule is 4-1BB, or CD137 which is expressed 
by activated T cells and plays a role in augmenting CTL responses during suboptimal 
stimulation (Williams and Bevan, 2007). The ligation of 4-1BB by T cells results in the 
secretion of IL-2 and the induction of cell division (Bertram et al., 2002). While the signals 
mediated through TCR/MHC interaction and through co-stimulatory molecules are 
sufficient to activate (or suppress) CD8 T cells, the development of an optimal CTL 
response requires a cytokine signal (Williams and Bevan, 2007). IL-12 and type 1 
interferons (IFNα/β) promote the expansion and differentiation of CTLs (Mescher et al., 
2006; Thompson et al., 2006). IL-12 is important in the development of CTL cytotoxicity 
by inducing IFNγ  production (Curtsinger et al., 2003) as well as the expression of 
granzyme B (Curtsinger et al., 2005). The expression of various transcription factors 
important in CTL differentiation is also induced by, or in part by, IL-12: T-bet (Joshi et al., 
2007; Takemoto et al., 2006) is crucial for differentiation of CD8 T cells into effector cells 
(Sullivan et al., 2003); STAT4 activation is mediated by IL-12 and IFNα/β, leading to 
IFNγ production (Nguyen et al., 2002); and Type 1 interferons also promote the survival of 
activated CD8 T cells (Marrack et al., 1999). The balance between these cytokines, IL-12 
and IFNα/β, varies depending on the infection (Cousens et al., 1999; Kolumam et al., 
2005). Of course, this is a rather simplified perspective, and it is more than likely that other 
cytokines play a role and influence the CD8 T cell-mediated response. Furthermore, much 
of what is known about the CD8 T cell response is due to studies in various animal viral 
models, and how the immune response plays out in humans in the context of pathogen 
clearance and autoimmune disease may not be quite the same. 
 After a CD8 T cell-mediated immune response, the majority of effector cells die via 
apoptosis, mediated through Bim (Hildeman et al., 2002; Pellegrini et al., 2003) and 
potentially other mechanisms. The proportion of cells that survive become memory T cells, 
characterized by relatively enhanced proliferation, the ability to survive for long periods of 
time, and increased ability to re-express effector genes (Parish and Kaech, 2009). In 
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addition, memory CD8 T cells express receptors for IL-7, promoting survival, and IL-15, 
driving antigen-independent proliferation (Williams and Bevan, 2007). 
 
1.2 Adaptive Immunity: Humoral response 
1.2.1 B cell development  
 B cells are derived from hematopoietic stem cells in the bone marrow. During 
development, they acquire antigen specificity; pro-B cells express TdT (Terminal 
deoxynucleotide transferase), a specialized template-independent DNA polymerase that 
catalyzes polymerization of deoxynucleoside triphosphates in vitro (Benedict et al., 2000), 
and RAG1 and RAG2, which are necessary for gene recombination of the B cell receptor 
(BCR) (Mesquita Junior et al., 2010). The BCR is an immunoglobulin, consisting of two 
heavy and two light chains linked by disulfide bonds. There are 5 heavy chains: α, γ, δ, ε, 
and μ which define the classes of immunoglobulins: IgA, IgG, IgD, IgE and IgM 
respectively. The light chains are kappa (κ) and lambda (λ). The heavy chain is made up of 
various segments: VH, D, JH and CL (Bonilla and Oettgen, 2010); the segments VH, D, and 
JH are rearranged and assembled under the influence of RAG. The heavy chain complex is 
associated with an invariable chain and expressed on the cell surface as a pre-BCR with 
two peptide chains, Igα and Igβ. These peptides, which play a role in BCR trafficking and 
signal transduction, have an N-terminal extracellular Ig-like domain, a single trans-
membrane domain and a cytoplasmic domain of 61 and 48 amino acids respectively 
(Defranco et al., 1995). Expression of the pre-BCR on the cell surface is followed by the 
rearrangement of the light chain κ; if a functional rearrangement fails, then the λ chain is 
rearranged. Antigen specificity is conferred by the variable regions of the heavy and light 
chains. The BCR of naïve B lymphocytes are IgM; co-expression of IgD marks a mature B 
cell (Zubler, 2001). Upon activation, the BCR undergoes class switching (Mesquita Junior 
et al., 2010). 
 Positive and negative selection follow the creation of a functional, intact BCR. 
Positive selection confers survival signals upon the B cells; negative selection takes place 
in the bone marrow. B cells that recognize self-antigen with high affinity will either 
undergo apoptosis or are given a second chance: RAG genes are re-activated and another 
light chain-VJ recombination is generated to substitute for an autoreactive combination 
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(Mesquita Junior et al., 2010). B cells recognizing self-antigens with weaker reactivity 
enter varying degrees of inactivation (i.e. anergy), but anergic cells still may be recruited in 
immune responses (Zubler, 2001). B cells migrating out of the bone marrow express 
various chemokine receptors and other molecules allowing them to migrate to specific 
areas within the body.  
 One subset of B cells, B1 in mice, migrate to the peritoneal tissues or cavities, the 
primary follicles of Peyer’s patches, and/or to the spleen and lymph nodes. Another B cell 
subset, B2, migrate to the splenic marginal zone, rich in macrophages and DCs, and 
favoring a T-independent response (Zubler, 2001). 
1.2.2 B cell activation 
 The BCR complex consists of the membrane immunoglobulin and two peptide 
chains, Igα and Igβ, which are responsible for signaling via ITAM motifs. Cross-linking of 
the BCR leads to clustering of the cytoplasmic domains of Igα and Igβ. Subsequent 
phosphorylation of the ITAM motifs mediated by src-family tyrosine kinases further 
recruits other tyrosine kinases (Syk or Lyn) (Defranco et al., 1995), thereby activating 
factors that promote the transcription of genes involved in the proliferation and 
differentiation of the B cell (Mesquita Junior et al., 2010). The activation of B cells can 
take place in one of two ways, depending on the type of antigen it interacts with. One 
response requires T cell help, initiated by T-dependent antigens; the other, independent of 
T cell help, is initiated by T-independent antigens (Bonilla and Oettgen, 2010). More 
recently, the role of TLRs in the activation of B cells is of increasing interest. 
 
1.2.2.1 T-independent antigens 
 Some macromolecules have repeating molecular patterns and can interact with and 
cross-link multiple immunoglobulin receptors on B cells. The (weak) activating signals 
transduced by cross-linking requires additional signals from cytokines or other cell 
contacts, provided by DCs (Bonilla and Oettgen, 2010).  
 
1.2.2.2 T-dependent antigens 
 B cells, like T cells, require more than one signal for optimal activation. B cells are 
activated by activated T cells which recognize the peptide presented on B cells via MHC 
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class II. The BCR will have recognized and captured the antigen, resulting in cross-linking 
of the BCR and induction of intracellular signaling, which leads to the production of 
additional molecules to enhance the B-T cell interaction and allows B cells to receive 
additional signals needed for full B cell activation (Bonilla and Oettgen, 2010). The 
interaction between B and T cell ultimately leads to each activating the other through the 
expression of various molecules and cytokines. Once activated, T cells express co-
stimulatory molecules such as ICOS, which interacts with the ligand B7RP-1 (ICOS-L) 
(Zubler, 2001). Interactions between various other molecules expressed on B and T cells 
lead to further stimulation and activation. Another important interaction is that between 
CD40L on activated T cells and CD40 on B cells, which also leads to induction of cytokine 
production (Mesquita Junior et al., 2010). Overall, the T-dependent activation of B cells is 
complex, and is not unidirectional, but rather each cell type induces the activation of the 
other. 
 
1.2.2.3 Toll-like receptor activation 
 TLRs are a subset of pattern recognition receptors (PRRs), usually found expressed 
by innate cells, but are also found in other cell types including B cells. In general, PRRs 
recognize PAMPs found on microbial organisms, which are foreign and absent on host 
cells (Janeway, 2001). TLRs are type 1 trans-membrane glycoproteins with leucine-rich 
repeat motifs on their extracellular domain and a Toll/interleukin-1R-interacting domain 
which contributes to cytoplasmic signaling via the MyD88 pathway (Booth et al., 2011), 
with the exception of TLR3 which mediates signaling through TRIF (Brown et al., 2011). 
Human B cells express moderate to high levels of TLRs 1, 6, 7, 9 and 10, and low levels of 
TLR 2; TLRs 3 and 4 are not found on human B cells (Booth et al., 2011). The levels of 
TLR found on B cells vary according to the B cell subset, thus affecting the sensitivity to 
TLR-mediated signaling and activation. Memory B cells, in general, express higher levels 
of TLR, and activation via TLR interaction with their ligands induces differentiation into 
Ab-producing plasma cells. On the other hand, naïve B cells express lower levels of TLR 
and thus respond weakly to TLR agonists (Booth et al., 2011). It has been demonstrated 
that activation of naïve B cells may be dependent on stimulation via TLR, and thus it has 
been proposed that TLR stimulation may be a required 3rd signal following BCR cross-
linking and T cell help (Ruprecht and Lanzavecchia, 2006). 
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 Following efficient activation via the TLR, B cells are able to proliferate, secrete 
cytokines and express co-stimulatory molecules. TLR stimulation was also shown to 
inhibit apoptosis (Ruprecht and Lanzavecchia, 2006). In the case of CpG, acting on TLR9, 
stimulation promotes BCR class-switching to IgG2a, IgG2b and IgG3, and inhibits IgG1 
and IgE switching (Lin et al., 2004; Liu et al., 2003). The secretion of immunoglobulins 
and cytokines requires additional signals concurrent to the CpG-induced signals. BCR 
cross-linking, CD40 ligation and factors such as BAFF and APRIL contribute to Ig 
secretion, whereas secretion of IL-6, IL-12 or IL-10 requires signals from CD40L or DCs 
(Booth et al., 2011).  
 Activation of B cells can occur in various ways, stimulation leading to different 
signaling pathways resulting in the expression of various cytokines and molecules 
important to mediating an immune response. Upon activation, B cells can either respond 
“directly” via antibody production, or also have a role in cytokine production which can 
modulate the immune response mediated by other immune cells. 
 
1.2.3 B cell responses 
 The primary B cell response, relatively slow to develop, involves the activation of 
naïve B cells and their differentiation into either short-lived plasma blasts which produce 
antibodies, or into memory cells. Upon activation, B cells go down one of two pathways; 
they either further differentiation into short-lived antibody-producing plasma blasts, or 
enter follicles and establish a germinal center where they undergo class-switching of the 
BCR (Bonilla and Oettgen, 2010). The primary response is dominated by the production of 
IgM Ab with relatively low affinity for Ag; other Ab classes appear later and show higher 
affinity for the cognate antigen (Bonilla and Oettgen, 2010). In the germinal center, the 
BCR changes from IgM or IgD to IgG, IgA or IgE. The gene arrangement involved in 
class switching is analogous to TCR and BCR rearrangement and involves genomic DNA 
rearrangement and alternative RNA splicing (Bonilla and Oettgen, 2010; Mesquita Junior 
et al., 2010). The variable regions of the immunoglobulin remain the same, so that the 
specificity for antigen does not change. It is the constant portion of the heavy chain which 
is replaced by one of the other chains, thereby diversifying the immune response since the 
different Ig classes each have a different function (Mesquita Junior et al., 2010). Class 
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switching and the resulting heavy chain is under cytokine influence. Various cytokines 
induce a switch to IgG (Zubler, 2001), IL-4 and IL-13 induce a switch to IgE, which is 
inhibited by IFNγ, and IL-10 and TGFβ have been shown to promote IgA (Bonilla and 
Oettgen, 2010).  
 In addition to producing antibodies, B cells have a role in cytokine production. For 
instance, B cells produce IL-10, which is primarily anti-inflammatory, but can be pro-
inflammatory under some conditions (Nikolajczyk, 2010). Activated B cells produce 
interleukins, TNF, macrophage inflammatory protein (MIP)1α and MIP1β. These factors 
modulate the migration of DC, activate macrophages, regulate T cell functions and also 
provide feedback signals further stimulating B cells (Dalakas, 2008). 
 Memory B cells can be of two sorts: the “conventional” memory B cells, or 
memory plasma cells (Yoshida et al., 2010). The former require restimulation with antigen, 
while plasma cells secrete specific antibodies for an extended time, long after the initial 
infection has been cleared, and persist independently of antigenic stimulation (Yoshida et 
al., 2010). The level of antigen required to elicit a response from memory B cells is lower 
than that for the response mediated by naïve B cells. In addition, the immune response 
mediated by memory B cells is faster, and antibody production reaches higher levels than 
the primary response (Mesquita Junior et al., 2010). While plasma cells depend on signals 
from BAFF and APRIL (see below), memory B cells require expression of a functional 
BCR complex, capable of mediating signaling (Yoshida et al., 2010). Interestingly, 
memory B cells can also be maintained via Epstein-Barr virus infection; the expression of 
viral receptors mimics regular activation signals, by-passing the direct need for BCR 
signaling (Yoshida et al., 2010). 
 B lymphocyte activator of the TNF family, or BAFF, is a potent stimulator of B 
cell maturation and survival. It is expressed by activated macrophages and DCs (Zubler, 
2001) in membrane-bound or soluble form (Schneider et al., 1999; Thangarajh et al., 2004) 
and interacts with transmembrane activator and CamL interactor (TACI), expressed on 
activated B cells. TACI has been shown to have a role in B cell homeostasis in addition to 
being a key mediator of class switching (Castigli et al., 2005b; Seshasayee et al., 2003). 
TACI is expressed on mature B cells and plasma cells (Hsu et al., 2002), and mutations are 
associated with IgA deficiency (Castigli et al., 2005a). APRIL (a proliferation-inducing 
ligand) shares properties and structural homology with BAFF (Schneider et al., 1999; 
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Thangarajh et al., 2004), also interacts with TACI, and is expressed on a range of 
leukocytes (Bonilla and Oettgen, 2010; Zubler, 2001). BAFF and APRIL have been 
implicated in the pathogenesis of various autoimmune diseases including multiple 
sclerosis, systemic lupus erythematosus, and rheumatoid arthritis. 
 
2.0 INTERLEUKIN-15 
 Interleukin-15 (IL-15) is a pleiotropic cytokine, expressed (at the mRNA level) in 
many tissues including kidney, lung, heart, skeletal muscle (Grabstein et al., 1994), and by 
various cell types under stimulatory conditions (Blauvelt et al., 1996; Jonuleit et al., 1997; 
Leclercq et al., 1996; Mohamadzadeh et al., 1995; Reinecker et al., 1996). However, in 
spite of this, the actual protein expression is not as widespread as the mRNA would 
indicate, and in fact translation is tightly regulated (Fehniger and Caligiuri, 2001). IL-15 is 
a member of the four α-helix family of cytokines which also include IL-2, IL-3, IL-6, IL-7, 
granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-
stimulating factor (GM-CSF) (Bazan, 1990a; Bazan, 1990b).  
 IL-15 was independently discovered by two groups based on its ability to mimic 
the effects of IL-2 in vitro (reviewed by (Waldmann, 2006)); however, in vivo, the effects 
of these two cytokines are very different (Fehniger and Caligiuri, 2001) demonstrated by 
using mice deficient in IL-15 (Kennedy et al., 2000) or IL-15Rα (Lodolce et al., 1998). 
The IL-15 and IL-2 receptors each have a unique alpha chain (Rα) which allows for the 
binding of the cytokine with high affinity. IL-2Rα expression is restricted to T cells for the 
most part, but is also expressed by DC (Wuest et al., 2011), while IL-15Rα overlaps with 
IL-15 in its expression at the mRNA level, and is found in almost every cell and tissue type 
(Anderson et al., 1995a; Giri et al., 1995). However, unlike the cytokine, IL-15Rα protein 
expression is not under similar regulation, and seems to parallel the transcript expression 
(Anderson et al., 1995b; Giri et al., 1995; Stonier et al., 2008). Interestingly, a pool of 
intracellular IL-15 is present in monocytes/macrophages, which is ready to be expressed on 
the surface as needed and independently of new protein synthesis (Neely et al., 2001). 
Signaling is mediated via a shared β chain (IL-2/15Rβ or CD122) (Bamford et al., 1994; 
Carson et al., 1994) and the common γ chain, also shared by IL-2, IL-4, IL-7, IL-9 and IL-
21 (Stonier and Schluns, 2010).  
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2.1 Structure of IL-15 and IL-15Rα 
 The IL-15 gene (Fig.1) contains 9 exons, 7 of which are coding exons (Fehniger 
and Caligiuri, 2001). An alternative exon has also been described, encoding for an 
alternative leader peptide, between exons 4 and 5 (Nishimura et al., 1998; Onu et al., 1997; 
Tagaya et al., 1997). The original IL-15 encodes for an IL-15 precursor protein with a long 
(48-amino acid (AA)) leader peptide (LSP) and a 114-AA mature protein; the alternate 
sequence encodes for a short signal peptide (SSP) of 21-AA (Fehniger and Caligiuri, 
2001). Both isoforms of IL-15 encode identical IL-15 protein, the only difference being in 
the signal sequence, and the localization of the final products: the LSP is secreted from the 
cell and/or placed into the cell membrane (Kurys et al., 2000; Onu et al., 1997), and the 
SSP remains localized to the cytoplasmic and nuclear compartments (Waldmann and 
Tagaya, 1999). The mature IL-15 protein is encoded by exons 5 to 8 of the IL-15 gene 
(Anderson et al., 1995b; Krause et al., 1996) and contains two disulfide bonds, one of 
which is homologous to that of IL-2 (Fehniger and Caligiuri, 2001). IL-15 has been 
predicted to have “helical moments” at four different sites in the protein (at AA 1-15, 18-
57, 65-78 and 97-114), supporting the model of a four α-helix bundle structure (Fehniger 
and Caligiuri, 2001).  
 IL-15Rα is a type-1 trans-membrane protein with eight isoforms (Waldmann and 
Tagaya, 1999) and has been shown to be highly homologous to the IL-2Rα subunit 
(Anderson et al., 1995a; Giri et al., 1995). Both contain a short cytoplasmic tail, a 
transmembrane domain, a hinge region and a sushi domain (most isoforms), which is 
required for cytokine binding (Anderson et al., 1995a; Giri et al., 1995; Waldmann, 2006). 
However, in contrast to IL-2Rα which has low affinity for IL-2 in the absence of IL-2Rβγ, 
IL-15Rα binds its cytokine with high-affinity, without the need for the rest of the receptor 
complex (Fehniger and Caligiuri, 2001). Furthermore, IL-15Rα is capable of reverse 
signaling; it was demonstrated to mediate a non-proliferative signal in the absence of IL-
2/15Rβ (Stevens et al., 1997) and hyper cross-linking of surface IL-15 resulted in 
activation of various signaling pathways including ERK 1/2 and MAPK (Neely et al., 
2004). However, for signaling to occur, the Rα chain is not absolutely necessary: IL-15 
may bind to IL-2/15Rβγ with intermediate affinity, in the absence of IL-15Rα (Giri et al., 
1994).  
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Fig.1: Diagram of IL-15 gene. IL-15 has two isoforms due to an alternate exon 
(4A) resulting in a short (21-AA) signal peptide (IL-15SSP) rather than the long (48-
AA) signal peptide (IL-15LSP). Adapted from (Bulfone-Paus et al., 2006). 
 
2.2 Signal transduction 
 The IL-15R complex signals through Jak1 and 3 as well as signal transducer and 
activator of transcription (STAT) 3 and 5 (Giri et al., 1995; Waldmann et al., 1998). IL-15 
was shown to activate the transcription factor NF-κB in neutrophils but not AP-1, while 
IL-15 stimulation of whole human peripheral blood lymphocytes activated both (Fehniger 
and Caligiuri, 2001). Additional signaling pathways may include src-related tyrosine 
kinases and through the Ras/Raf/MAPK pathway leading to fos/jun activation (McInnes 
and Gracie, 2004). However, it must be noted that signaling related to IL-15 does not occur 
in the conventional manner as with other cytokines.  
 A study in which T cell proliferation mediated by IL-15 did not require IL-15Rα 
expression on the responding T cells but rather required IL-15Rα expression by 
surrounding cells (Lodolce et al., 1998) was the first indication of a unique manner by 
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which IL-15 signaling is mediated. As the direct effect of IL-15 in inducing T cell 
proliferation had already been established, it was unlikely their observations were due to an 
indirect effect mediated by IL-15 (Stonier and Schluns, 2010). Another group soon 
proposed a mechanism of IL-15 trans-presentation (depicted in Fig. 2), demonstrating a 
prolonged effect on T cells by IL-15 relative to IL-2, despite IL-15 withdrawal from the 
media (Dubois et al., 2002). This was demonstrated to be mediated by the strong 
association of IL-15 with IL-15Rα, allowing the receptor alpha chain to maintain IL-15 on 
the cell surface and enhance the persistence of IL-15 signaling (Dubois et al., 2002). 
Furthermore, IL-15 and IL-15Rα were shown to associate intracellularly and were 
followed from the endoplasmic reticulum to the cell surface (Dubois et al., 2002). 
  
 
Fig.2: Trans-presentation of IL-15. IL-15/IL-15Rα-expressing cell presents IL-15 in trans to 
effector cells expressing either IL-15Rβγ or IL-15Rαβγ. Adapted from (Bulfone-Paus et al., 2006) 
 
2.2.1 Regulation of trans-presentation 
 At the most basic level, trans-presentation requires IL-15 and IL-15Rα to be 
transcribed in the same cell. However, it is not yet known if up-regulation of transcription 
will be sufficient to increase the IL-15 being trans-presented (Stonier and Schluns, 2010). 
It is known that there are several mechanisms in place at the post-transcriptional level 
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(discussed later) which would limit the availability of IL-15 for trans-presentation. Similar 
mechanisms regulating IL-15Rα have not been identified, which perhaps explains the 
higher prevalence of IL-15Rα compared to IL-15. Another level of regulation after limited 
protein expression is the transport of IL-15 to the cell surface. It has been reported that IL-
15Rα is required for IL-15 to be transported from the endoplasmic reticulum to the cell 
surface (Duitman et al., 2008). Furthermore, IL-15Rα bound to IL-15 can be internalized 
and later return to the surface (Dubois et al., 2002) which may promote the need for 
regulating cytokine production, or may be an additional level of control, to limit the 
availability of IL-15 as needed. 
 Another factor to consider limiting the availability of IL-15 to cells could simply be 
cellular localization. For trans-presentation to occur, a responsive cell must be in close 
proximity to the cell presenting IL-15. It is thus highly probable that rather than randomly 
encountering IL-15 presenting cells, responsive cells would be directed to the source 
(Stonier and Schluns, 2010).  
 
2.3 Expression of IL-15: regulation 
 IL-15 mRNA is found in many cell types, but protein expression is limited and 
regulated through multiple mechanisms. IL-15 production is regulated at both the 
transcriptional and posttranscriptional levels. Several binding sites for transcription factors 
were identified in the promoter regions of human and murine IL-15 (Fehniger and 
Caligiuri, 2001). There are three main “checkpoints” which regulate translation of IL-15 
mRNA (Fehniger and Caligiuri, 2001): first, the existence of multiple start codons in the 5’ 
untranslated region (UTR); the LSP and SSP themselves; and negative regulation near the 
C terminus of the protein precursor. 
 The LSP IL-15 5’ UTR is relatively long and contains multiple AUGs upstream of 
the translation start site, which impedes translational efficiency (Bamford et al., 1996; 
Fehniger and Caligiuri, 2001). The removal of most of the upstream AUG sequences in the 
5’ UTR resulted in a 5- to 10-fold increase in IL-15 protein expression (Bamford et al., 
1996). It was also demonstrated that LSP IL-15 is translated with lower efficiency than 
SSP IL-15 (Tagaya et al., 1997); also considering the localization of each of the two 
isoforms, we see a tight regulation of protein expression. SSP IL-15 is more efficiently 
 31
translated, but is localized to the nucleus and cytoplasmic regions, and is not secreted. Not 
only is LSP IL-15 is less efficiently translated, but also is secreted from the cell and/or 
inserted into the cell membrane at low levels (Fehniger and Caligiuri, 2001; Kurys et al., 
2000). Finally, it was suggested that a signal in the C terminus of the mature IL-15 protein 
is responsible for inefficient secretion (Fehniger and Caligiuri, 2001); since the activity of 
a LSP-IL-15-GFP construct was significantly higher than that of LSP-IL-15 
(approximately 10 times more labeled IL-15 was secreted), the authors suggested the GFP 
tag masked a retention signal in the C terminus (Gaggero et al., 1999). 
 If all three of these “checkpoints” are removed – removing upstream AUG 
sequences, replacing IL-15 leader peptide with that of IL-2 and changing the C terminus 
end of the protein, synthesis of IL-15 increased by 250-fold (Bamford et al., 1998). The 
extent to which the expression of IL-15 is regulated indicates that overproduction would be 
dangerous. There is some evidence to support this: transgenic mice over-expressing IL-15 
develop a fatal lymphocytic leukemia (Fehniger et al., 2001), and IL-15 is consistently 
upregulated in leukemic cells of childhood acute lymphoblastic leukemia patients with 
CNS involvement (Cario et al., 2007).  
  
2.4 The role and effect of IL-15 
 IL-15 is important in the development, homeostasis and activity of NK cells and γδ 
T cells, and plays a role in the survival and expansion of naïve and memory CD8 T cells. It 
also has an effect on other immune cells, as well as on non-immune cells such as 
fibroblasts, epithelial and endothelial cells, and neuronal and glial cells.  
 IL-15 is important in the survival and expansion of naïve and memory CD8 T cells 
(Alves et al., 2003; Berard et al., 2003); homeostatic proliferation in response to IL-15 
allows for the self-renewal and maintenance of memory CD8 T cells over long periods of 
time (Becker et al., 2002; Goldrath et al., 2002). Mice deficient in IL-15 or IL-15Rα have a 
marked decrease in the number of memory CD8 T cells and, to a lesser extent, in the 
number of naïve CD8 T cells, but have normal levels of CD4 and B cells (Kennedy et al., 
2000; Lodolce et al., 1998); IL-15Rα deficient mice are, in addition, impaired in thymic 
CD8 T cell development (Lodolce et al., 1998).  
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 Naïve T cells can proliferate in response to high concentrations of IL-2 and IL-15, 
as long as they also receive a signal via the TCR through MHC recognition (Cho et al., 
2007; Ramsey et al., 2008). Also supporting a role for IL-15 in homeostatic proliferation, 
mice deficient in IL-15 have about half the number of naïve CD8 T cells relative to wild 
type mice (Berard et al., 2003; Ramanathan et al., 2006). Involved with the regulation of 
the naïve T cell response to IL-15 is SOCS-1, which is up-regulated in response to IL-15 
(among other cytokines) (Yoshimura et al., 2007). Deficiency in SOCS1 increases the 
sensitivity of double positive thymocytes to both IL-7 and IL-15 (Chong et al., 2003; 
Ramanathan et al., 2006) and results in mature CD8 T cells that are hyper-sensitive to IL-
15 (Davey et al., 2005; Ramanathan et al., 2006). Mice deficient in SOCS1 (restricted to T 
cells) have CD8 T cells of primarily a memory phenotype (Davey et al., 2005). Overall, as 
a regulator of the cellular response to IL-15, SOCS1 might be involved in controlling 
antigen-independent activation of naïve CD8 T cells under inflammatory conditions, to 
prevent expansion of potentially autoreactive CD8 T cells (Ramanathan et al., 2008). 
 Along with IL-7, IL-15 has a crucial role in the MHC-independent homeostasis of 
memory CD8 T cells (Surh and Sprent, 2008). While the expansion of memory CD8 T 
cells under the influence of IL-7 occurs only in lymphopenic hosts, IL-15 is able to support 
and favor the generation of memory CD8 T cells in mice with an intact T cell compartment 
(Surh and Sprent, 2008). One of the first indications that cytokines were involved in the 
maintenance of memory T cells, the injection of adjuvants resulted in an increase in the 
proliferation of memory CD8 T cells (Surh and Sprent, 2008). Further investigation 
showed that such adjuvants (e.g. LPS or PolyI:C) stimulated the production of type-1 
interferons, which promoted the synthesis of IL-15 on APCs; this IL-15 was shown to act 
on memory CD8 T cells and enhance the rate of homeostatic proliferation (Zhang et al., 
1998). Administering IL-15 to IL-15 deficient mice increased the proportion and number 
of CD8 memory T cells in the spleen and lymph nodes (Berard et al., 2003), and further 
outlining a crucial role for IL-15, memory CD8 T cells transferred into IL-15 deficient 
mice failed to proliferate and died rapidly (Judge et al., 2002). 
  
 33
2.5 IL-15 in disease 
 Activation of CD8 T cells, while beneficial in protective immune responses, can 
also contribute to chronic inflammatory disorders as well as to the progression of 
autoimmune diseases due to their ability to directly kill target cells. CD8 T cells have been 
implicated in various autoimmune diseases (reviewed by (Walter and Santamaria, 2005). 
IL-15, being one of the cytokines involved in the homeostatic maintenance of CD8 T cells, 
is an ideal candidate for potentially aberrant CD8 T cell activation. This cytokine facilitates 
the maintenance and triggering of autoreactive CD8 T cells (Itsumi et al., 2009; Peng et al., 
2006; Ramanathan et al., 2011) and plays a crucial role in CD8 T cell migration and 
survival in organs (McGill et al., 2010; Verbist et al., 2011). Indeed, IL-15 has been 
implicated in various diseases, including those in which CD8 T cells have also been 
implicated: rheumatoid arthritis (RA), inflammatory bowel diseases (IBD), type 1 diabetes, 
psoriasis, as well as various CNS disorders (Davey et al., 2005; Liu et al., 2000; McInnes 
and Gracie, 2004; McInnes and Liew, 1998; Ramanathan et al., 2011; Rentzos and 
Rombos, 2011; Sakai et al., 1998).  Furthermore, due to its ability to activate T cells, IL-15 
is also under investigation regarding its potential in anti-tumor immunotherapy (Hanson et 
al., 2000; Jakobisiak et al., 2011; Klebanoff et al., 2011) and as a factor to improve vaccine 
efficacy (Hu et al., 2009; Huntington et al., 2011; Yu et al., 2011). 
 
2.5.1 Rheumatoid Arthritis 
 IL-15 protein has been detected in synovium and in RA joint lesions (Thurkow et 
al., 1997). Synovial fluids were demonstrated to promote the migration and activation of T 
cells, which was partially inhibited by the addition of antibodies antagonistic to IL-15 
(McInnes et al., 1996). Furthermore, IL-15 activated T cells from RA patients were able to 
stimulate macrophage cell lines as well as primary monocytes and macrophages to produce 
TNFα in vitro. Phase II clinical trials using an anti-IL-15 human monoclonal antibody 
(AMG 714) have been completed (NCT00433875, http://www.clinicaltrials.gov), and the 
same antibody is also being currently tested for psoriasis in a phase II trial 
(NCT00443326).  
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2.5.2 Inflammatory Bowel Diseases 
 IL-15 mRNA has been detected in macrophages and epithelial cells from patients 
with active IBD and has been detected at the protein level in the supernatants of rectal 
mucosal biopsy samples (Sakai et al., 1998). Mention et al. showed that IL-15 was not 
secreted, but rather was presented at the surface of enterocytes in celiac disease (Mention 
et al., 2003). In addition, T cells isolated from the lamina propria of IBD patients showed a 
greater responsiveness to IL-15 as compared to controls, not only producing IFNγ and TNF 
in response to IL-15 stimulation, but also inducing the production of pro-inflammatory 
cytokines in monocytes in vitro (Liu et al., 2000). In conjunction with retinoic acid, IL-15 
induced the production of IL-12p70 and IL-23 by DC (DePaolo et al., 2011). Not only 
does the elevated levels of IL-15 seem to induce the production of various pro-
inflammatory cytokines, but also is able to stimulate CD8 T cells to be cytotoxic. Studies 
have shown increased induction of NKG2D in response to elevated levels of IL-15 
(Meresse et al., 2004; Roberts et al., 2001), and that NKG2D serves as a co-stimulator for 
CTL (Roberts et al., 2001), activating CTL functions independently of TCR 
specificity(Meresse et al., 2004). 
 
2.5.3 Type 1/autoimmune diabetes 
 Serum IL-15 has been detected in patients with type 1 diabetes and levels were 
significantly higher as compared to controls (Kuczynski et al., 2005). In a mouse model of 
autoimmune diabetes, it was shown that stimulation with IL-15 and IL-21 enabled CD8 T 
cells to respond to weak antigens, inducing proliferation, cytokine secretion and cytolytic 
activity (Ramanathan et al., 2011). Furthermore, increased sensitivity to IL-15 via SOCS1 
deficiency can result in the activation of autoreactive CD8 T cells in a model of type 1 
diabetes (Davey et al., 2005). 
 
2.5.4 CNS disorders 
 IL-15 has been demonstrated to be elevated in various CNS disorders: patients with 
Alzheimer’s disease or frontotemporal dementia had higher levels of IL-15 detected in 
their cerebrospinal fluid (CSF) as compared to patients with non-inflammatory 
neurological disease (Rentzos et al., 2006). An increase in circulating IL-15 was detected 
in levadopa-treated patients with advanced Parkinson’s disease and functional impairment 
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(Gangemi et al., 2003). In multiple sclerosis (MS), which not only involves the CNS, but is 
also an autoimmune disease, IL-15 and IL-15Rα have been detected at the mRNA level in 
the CNS (Hanisch et al., 1997; Kurowska et al., 2002; Lee et al., 1996), and at the protein 
level, expressed on the surface of monocytes from MS patients (Vaknin-Dembinsky et al., 
2008).  
 A role for IL-15 in CNS disorders is further indicated upon examination of various 
animal models. The neuronal localization of IL-15 and IL-15Rα has been demonstrated in 
mice (Wu et al., 2010), and is expressed in the cerebellum and hippocampus(Gómez-
Nicola et al., 2008a). IL-15 seems to be mainly expressed by astrocytes and microglia 
(Gómez-Nicola et al., 2008b), but has also been described to be expressed in some 
projection neurons (Gómez-Nicola et al., 2008a). In a mouse model of facial nerve 
axotomy, fewer T cells and activated microglia were found in IL-15 or IL-15Rα knockout 
mice than in wild type mice (Wu et al., 2010). This cytokine seems to play a role in the 
development of early inflammatory events. In a model of spinal cord and sciatic nerve 
constriction injury, IL-15 was expressed by astroglial and microglial cells in the spinal 
cord and acted as a cue for macrophage and T cell activation and infiltration (Gómez-
Nicola et al., 2008b). Under inflammatory conditions, as demonstrated using a model of 
acute inflammatory injury using LPS injection, astrocytes and microglia expressed 
elevated levels of IL-15 (Gómez-Nicola et al., 2008a).  
 The role of IL-15 in MS pathogenesis is of specific interest, when the involvement 
of CD8 T cells is also considered, and warrants further investigation.  
 
3.0 MULTIPLE SCLEROSIS  
 Multiple Sclerosis is considered to be a T cell-mediated autoimmune disease of the 
central nervous system, where myelin-specific T cells enter the CNS and cause damage in 
genetically susceptible individuals. The disease is characterized by the infiltration of 
various immune cells and their presence in and around lesions (Frohman et al., 2006), 
demyelination, and axonal injury (Lassmann et al., 2001; Trapp et al., 1998). While under 
“normal” conditions the CNS retains its immune privileged status, inflammatory processes 
breach the integrity of the blood-brain barrier thereby allowing entry of immune cells into 
the CNS.  
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 The majority of cases (80-90%) of MS begin with a relapsing-remitting disease 
course (RRMS). As the disease progresses, the number of relapses decreases but patients 
enter a secondary progressive phase (SPMS) characterized by a decrease in inflammation 
but an increase in disability. A fraction of patients with MS do not have relapses, but rather 
have a primary progressive course of disease (PPMS) (Hemmer et al., 2002). In patients 
with RRMS, acute CNS lesions are commonly detected (Hemmer et al., 2002) 
characterized by perivascular infiltration by lymphocytes, demyelination, glial cell 
activation, axonal damage and the presence of myelin-laden macrophages (Frohman et al., 
2006). In PPMS or SPMS, inflammatory activity is not as prominent as in RRMS, but 
rather brain atrophy is dominant and correlates with disability (Hemmer et al., 2002). 
The inflammatory processes involved in multiple sclerosis cannot be described in a 
linear fashion, beginning with a triggering event followed by the response from the 
immune system subsequently leading to damage. The initial events or the factors involved 
leading to the development of multiple sclerosis still remains an enigma; there are various 
perspectives regarding this question: whether the causes are genetic (Hillert and Olerup, 
1993; International Multiple Sclerosis Genetics Consortium, 2011), environmental (Gale 
and Martyn, 1995), viral (Kakalacheva et al., 2010; Santon et al., 2011; Sibley et al., 1985) 
or due to vitamin D levels (Albert et al., 2009; Smolders et al., 2009). However, while we 
do not know as yet the initiating events for MS, we can indirectly observe what is going on 
during disease progression through the examination of factors and cells present in the 
blood and CSF of patients, in post-mortem tissue, or by using animal models. 
 
3.1 Animal Models of MS 
 Multiple sclerosis is a human disease, of unknown etiology. Furthermore, it is quite 
complex, involving contradictory processes: attacks and remission, demyelination and 
remyelination, inflammation and suppression of inflammation, all leading to progressive 
disability in patients. While no animal model can mimic all features of the disease, they are 
still useful in allowing us to learn about and understand various aspects of disease and the 
contributions from the immune system and CNS in neuroinflammation. Indeed, thus far 
they have contributed much to our understanding of some of the basic processes in MS. 
There are two main types of models (Pachner, 2011): autoimmune and virus-induced 
(although viral models also have autoimmune responses). 
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3.1.1 Experimental Autoimmune Encephalomyelitis 
 Experimental autoimmune encephalomyelitis (EAE), ironically, is an animal model 
developed based on observations in humans. In some instances of patients receiving Louis 
Pasteur’s rabies vaccine (Pachner, 2011), patients developed an ascending paralysis from 
the lower limbs to the upper limbs and neck, eventually affecting swallowing and 
breathing. In milder cases, paralysis was mild and recovery rapid (Baxter, 2007). Later 
investigation using brain extracts and rhesus monkeys presented the first instances of 
vaccine-induced encephalomyelitis (Baxter, 2007; Pachner, 2011). Following these first 
experiments, other groups boosted the immune response by injecting brain emulsions 
mixed with paraffin oil and Mycobacterium tuberculosis, an adjuvant described by Freund 
(Baxter, 2007). The resulting EAE could now be consistently induced in animal models. 
Depending on the animal used, the clinical signs and disease pathology will vary (Baxter, 
2007). 
 Rats were the animal of choice in MS research (Croxford et al., 2010); the disease 
is consistent and rather straightforward to induce in Lewis rats. EAE is characterized by 
acute onset of disease followed by spontaneous recovery, resembling the relapses and 
remissions in MS. However, disease is localized to the spinal cord, and no demyelination is 
present (Croxford et al., 2010). Over the years, mice became a more common choice for 
induction of EAE and MS studies. It could simply have been a matter of what tools were 
available; more reagents were generated for use in mice than in rats, antibodies for use in 
flow cytometry were generated against mouse (and human) antigens, and, finally, the 
existence of various inbred genetic backgrounds and knockouts in mice made it possible to 
study the effects and involvement of specific factors in disease (Croxford et al., 2010), 
while minimizing variability in disease between groups (Pachner, 2011). 
 
3.1.1.1 Characteristics of EAE 
 The disease course of EAE can be acute, chronic, or relapsing-remitting, depending 
on the genetic background, immunogen and the use of pertussis toxin (Stromnes and 
Goverman, 2006a). In general, myelin-specific CD4 T cells are activated in the periphery 
whereupon they cross the blood-brain barrier (BBB) into the CNS. APC present in the 
CNS re-activate infiltrating T cells via peptide presentation on MHC class II with co-
stimulatory molecules thus initiating an immune response perpetuating inflammation and 
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damage (Stromnes and Goverman, 2006a). Events in EAE include the secretion of 
chemokines which recruit macrophages to sites of T cell activation, of pro-inflammatory 
molecules such as TNFα and IL-1, important in inflammation and CNS tissue damage 
(Stromnes and Goverman, 2006a). Some other features of EAE, also seen in MS, are 
destruction of the myelin sheaths, the presence of CNS lesions (more in the brain stem and 
spinal cord of EAE models), axonal injury, the infiltration of immune cells and the 
presence of immunoglobulin in the CNS and CSF (Baxter, 2007).  
 In rodent models of EAE, disease is typically characterized by an ascending 
paralysis, beginning with a limp tail and progressing to the hind and forelimbs. Disease 
course is typically scored on a scale from 0 to 5. There is no one universal scale for scoring 
EAE, but typically main “points” in disease are a limp tail, ataxia, hind limb weakness 
and/or paralysis in one or both limbs, forelimb weakness and/or paralysis and finally, a 
moribund state. Variations to the classical EAE disease course do occur (Muller et al., 
2000), and is termed atypical EAE. Atypical disease usually involves active induction of 
EAE, but it has been observed in the adoptive transfer of wild-type or IFNγ deficient T 
cells (Stromnes and Goverman, 2006b). While in classical EAE, symptoms are indicative 
of inflammation and damage localized to the spinal cord, inflammation is localized more in 
the brain in atypical EAE (Muller et al., 2000; Stromnes and Goverman, 2006b).  
 
3.1.1.2 Induction: Active vs. Passive EAE 
 Most protocols for the induction of EAE use purified encephalitogens, including 
myelin basic protein (MBP), proteolipid protein (PLP) and myelin oligodendrocyte 
glycoprotein (MOG); recombinant myelin proteins; or synthetic peptides derived from 
myelin proteins (Pachner, 2011; Stromnes and Goverman, 2006a). 
 Active EAE is induced via immunisation of susceptible rats or mice with CNS 
protein in complete Freund’s adjuvant, with or without simultaneous injection of pertussis 
toxin, depending on the strain, to promote opening of the BBB. It can take from 9-20 days, 
typically, for symptoms to begin to manifest (Stromnes and Goverman, 2006a).  
 Passive EAE involves the adoptive transfer of immune cells from immunized 
animals to naïve hosts. Transferred cells can be lymph node cells, T cells, or even specific 
subsets of cells, all of which are sufficient to induce disease (Stromnes and Goverman, 
2006b). In passive EAE, cells can be labelled before transfer, so that localization and 
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activity can be monitored. Furthermore, the effector functions can be manipulated via pre-
stimulation in vitro before transfer, so that the relevance of a particular cell subset may be 
examined in the disease pathogenesis (Stromnes and Goverman, 2006b). Most commonly, 
passive EAE models involve the transfer of CD4 T cells; fewer models involve transfer of 
CD8 T cells (Wekerle, 2008). 
3.1.1.3 Transgenic mouse models 
 Transgenic mouse models are useful in that they can help expose and elucidate the 
potential role of components of the immune system in triggering disease induction. Often, 
these models involve constitutive expression of a molecule, or myelin-specific TCRs, 
resulting in spontaneous disease development.  
 One such model resulting in demyelination in mice, involves the constitutive 
expression of B7.2 (CD86), a co-stimulator of T cells, on microglia. This seems to induce 
the infiltration of the CNS by primarily CD8 memory-effector T cells, as well as CD4 T 
cells. Transfer of T cells into T cell-deficient B7.2 transgenic hosts induces disease, 
implying a role for the co-stimulatory signal on T cells in disease induction and 
development (Zehntner et al., 2003).  
 Another model expresses a myelin-specific T cell receptor towards MOG. While it 
would be expected that disease spontaneously develops in such mice, interestingly disease 
develops in MOG-deficient mice. Upon further examination, it was found that the MOG-
specific TCR also recognizes neurofilament-M, a neuronal cytoskeletal protein 
(Krishnamoorthy et al., 2009). The authors suggest that cumulative responses – reactivity 
of specific T cells to more than one antigen – could result in spontaneous development of 
autoimmune disease in humans. 
 
3.1.1.4 Limitations of EAE 
 Of course, being only a model for disease, there are some limitations for EAE as a 
model of MS. As the etiology of MS is currently unknown, EAE cannot be used to study 
potentially triggering events in the pathogenesis of MS especially as it is induced by 
immunization with myelin antigens or via adoptive transfer. Furthermore, there are no 
models which spontaneously develop disease except transgenic mice. Another factor to 
consider is that the myelin peptides used to initiate disease may be different from those 
actually inducing disease in multiple sclerosis and so the factors seemingly involved in 
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disease pathogenesis may not be relevant to the human disease. Lastly, the active induction 
of EAE is skewed towards a CD4 T cell response; however, increasing evidence shows 
that other immune cells play an important role in disease pathogenesis as well, including 
CD8 T cells, B cells, and various innate immune cells. However, despite limitations of the 
model, it has been useful thus far in understanding inflammation in the CNS not only as it 
relates to MS, but also to other inflammatory conditions in the CNS, and will continue to 
be so. 
 
3.2 Multiple Sclerosis and the Immune System 
3.2.1 The immune system and the CNS 
 The CNS is traditionally seen as an immune-privileged site, due to the existence of 
the BBB, a barrier made up of tight junctions between brain endothelial cells. The BBB 
serves to restrict the entry of solutes and ions (Carson et al., 2006) as well as immune cells 
(Hawkins and Davis, 2005; Mrass and Weninger, 2006) into the CNS. However, the 
selectivity of the BBB does not necessarily mean it is completely exclusive; cell migration 
occurs at the post-capillary venules, and is controlled by adhesion molecules, cytokines 
and chemokines and their corresponding receptors (Owens et al., 2008).  
 In general the CNS creates an immunosuppressive environment: various 
neuropeptides and transmitters in addition to various neuronal membrane proteins such as 
CX3CL1 (fractalkine), intracellular adhesion molecule (ICAM)-5, neural cell adhesion 
molecule (NCAM) and semaphorins all contribute to regulating inflammation (Tian et al., 
2009), and the presence of factors such as transforming growth factor-1 in the 
microenvironment created by neurons favor the differentiation of regulatory T cells (Amor 
et al., 2010). Furthermore, the CNS is capable of defending itself against immune 
infiltration: astrocytes can suppress both Th1 and Th2 cell activation and are capable of 
causing T cell apoptosis (Bechmann et al., 2002), and it has also been shown that neurons, 
too, can induce T cell apoptosis (Tian et al., 2009). In addition, the basal expression level 
of MHC molecules in the CNS is quite low, thus contributing to limiting the autoimmune 
response against CNS cells. 
  The infiltration of immune cells occurs during neuroinflammation upon the release 
of inflammatory mediators by activated microglia which increase BBB permeability 
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(Popescu et al., 2009). CD4 T cells have been observed in the CNS of MS patients, and 
CD8 T cells have been shown to be in close contact with neurons, indicating that neuronal 
damage is mediated by cytotoxic CD8 T cells (Neumann et al., 2002). Neurons can also 
promote immune activation via the secretion of chemokines, complement factors, and 
damage-associated molecular pattern molecules (Amor et al., 2010). The presence of T 
cells in the brain also affects glial function, with Th1 and Th17 cells increasing microglial 
activation (McQuillan et al., 2010; Murphy et al., 2010). However, not all immune 
responses within the CNS are detrimental; they can also aid in repair and regeneration. 
 Microglia play an important role in promoting repair; for instance, they clear debris 
after myelin damage, and impeding this process results in delayed regeneration (Neumann 
et al., 2009). Interestingly, it would seem that T cells can also aid in recovery and have a 
role in repair and protection, although the specific mechanisms of such effects are as yet 
unclear (Hohlfeld, 2008; Schwartz et al., 2009). For instance, T cell responses include the 
production of neuroprotective factors such as brain-derived neurotrophic factor (Hohlfeld, 
2008; Kerschensteiner et al., 2003). Additionally, far from being only destructive, it has 
been shown that autoimmune T cells can also aid in the repair of the CNS (Hofstetter et al., 
2003; Nielsen et al., 2009). 
 
3.2.2 Inflammation in MS 
 While MS has long been considered to be a T-cell mediated autoimmune disease, 
there are, of course, various other factors also at play. Not only are T cells involved, but 
also B cells, innate immune cells, and the cells of the CNS are all involved in modulating 
the immune reactions taking place.  
   
3.2.2.1 Innate immunity 
Microglia are the resident immune cells of the CNS. In their resting state, they have 
a ramified structure and express low levels of immunological molecules. However, while 
in a ‘resting’ state, they are continuously monitoring a defined area within the CNS 
(Davalos et al., 2005; Nimmerjahn et al., 2005). Upon injury or disruption to the BBB, 
microglia become activated immune-competent cells, increasing the expression of MHC 
Class I and II molecules (Kreutzberg, 1996) and extending their processes or migrating 
towards sites of injury (Cho et al., 2006; Davalos et al., 2005; Nimmerjahn et al., 2005). In 
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multiple sclerosis, inflamed glial cells produce pro-inflammatory cytokines such as IL-1β, 
tumor necrosis factor (TNF)-α, and various chemoattractant molecules such as CXCL10, 
CCL2 and CCL5 which attract microglia to lesion sites and which promote the invasion of 
peripheral immune cells (Kierdorf et al., 2010). Furthermore, with the activation of 
microglial cells, they serve as APCs and can potentially present brain-derived antigen to 
invading T cells. Facilitating the entry of immune cells into the CNS, endothelial cells 
produce chemokines such as CCL19 and CCL21 which serve to guide T cells to enter the 
injured tissue (Alt et al., 2002). 
 
3.2.2.2 MS and inflammation: the role of T cells 
 The implication and role of T cells in the pathogenesis of multiple sclerosis is long-
standing. Many studies have examined the frequency of myelin-specific T cells in patients 
with multiple sclerosis as compared to healthy controls. However, while often no 
significant difference in frequency was found between the two groups (Ota et al., 1990; 
Pette et al., 1990), it was reported that a higher frequency of myelin-specific T cells from 
MS patients did have a memory or activated phenotype, while the same Ag-specific T cells 
in healthy donors have a naïve phenotype (Bielekova et al., 2004; Lovett-Racke et al., 
1998; Scholz et al., 1998). Additionally, differences in the expression of chemokine 
receptors and cytokines by myelin-specific T cells also suggest that these cells are more 
inflammatory in MS patients (Crawford et al., 2004; Kivisäkk et al., 2004). 
 The commonly held theory regarding the pathogenesis of MS is that it is primarily 
a CD4 T cell-mediated disease (Delgado and Sheremata, 2006; Kuchroo et al., 2002; 
Steinman, 1996). The pathology seen in EAE is similar to that in MS patients (Goverman, 
2009) and supports the involvement of CD4 T cells. The induction of EAE favours the 
activation of CD4 T cells (Goverman, 2009), disease induction via adoptive transfer of 
myelin-specific CD4 T cells was shown to be possible (Baron et al., 1993), and human 
studies show genetic susceptibility to developing MS is associated with MHC class II 
genes ((Hillert and Olerup, 1993) reviewed by (Batoulis et al., 2010)). Thus, it was thought 
that the primary effector cells in the pathogenesis of MS were CD4 T cells.  
 Much early research was thus focused on the role of these cells, and more 
specifically on the Th1 response (Batoulis et al., 2010), but while CD4 T cells continue to 
be studied, further research since then has opened doors for the involvement of  not only 
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Th1 but also Th17 cells, as well as CD8 T cells in disease pathogenesis. For instance, 
while relatively higher numbers of CD4 T cells are found in active MS lesions, they are not 
present in chronic MS lesions (Chitnis and Alireza, 2007), and in some cases greater 
numbers of CD8 T cells than CD4 T cells have been detected in MS lesions (Babbe, 2000; 
Frischer et al., 2009; Hauser et al., 1986). Generally, the accumulation of T cells in brain 
tissue depends on MHC restriction in addition to local antigen recognition(Flugel, 2001). 
Infiltrating CD4 T cells tend to be localized at the perivascular cuffs and close to the 
meninges, while CD8 T cells invade the parenchyma of the inflamed CNS (Kawakami et 
al., 2005) and are enriched at the site of actively demyelinating lesions(Neumann et al., 
2002). 
 Research has demonstrated different roles for subsets of CD4 T cells in the 
pathogenesis of MS – and in other autoimmune diseases. In general, it is suggested that 
inflammatory responses in autoimmune disease are mediated by inflammatory Th1 cells 
(Liblau et al., 1995), requiring IL-12 for differentiation, and producing lymphotoxin and 
IFNγ, but little IL-4 (Mosmann and Coffman, 1989). Various evidence supports this idea: 
administration of IFNγ to MS patients exacerbated the disease (Panitch et al., 1987); 
myelin-reactive T cells from MS patients produce cytokines consistent with a Th1 
response (Crawford et al., 2004); and increased activity in MS was related to the levels of 
IFNγ and IL-12 found in the CNS and CSF of patients (Gutcher and Becher, 2007). This is 
further supported by findings in EAE: T cells infiltrating the CNS secrete IFNγ, IL-12 is 
detected in inflammatory lesions (Baron et al., 1993; Segal and Shevach, 1996) and the 
transfer of autoreactive CD4 T cells is well established in inducting disease (Baron et al., 
1993; Stromnes and Goverman, 2006b). Considering the effects of IFNγ: the ability to 
induce MHC Class II expression on CNS cells, activate macrophages, promote T cell 
homing (Navikas and Link, 1996) and even induce oligodendrocyte death (Vartanian et al., 
1995), there is a strong case for the role of IFNγ-producing Th1 cells in the inflammatory 
response in the CNS. However, in spite of such evidence for the role of Th1 cells in MS 
pathogenesis, it does not quite pass muster upon further examination. 
 First, mice deficient in IL-12, IFNγ and TNF developed worse EAE than controls 
(Steinman, 2007). IL-12 is a heterodimer consisting of two subunits: p40 and p35; it was 
shown that depending on which subunit was lacking, the susceptibility to disease induction 
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in mice was varied. Mice lacking the p40 subunit did not develop EAE (Becher et al., 
2002), but mice lacking the p35 subunit were more susceptible to developing disease (Gran 
et al., 2002). It is worth noting that IL-12 shares the p40 subunit with another interleukin, 
IL-23 (Gran et al., 2002). Lastly, mice deficient in IL-23 were resistant to disease, but had 
a normal Th1 response (Cua et al., 2003) further indicating that perhaps it is not Th1 cells 
which are the primary cells mediating the inflammatory response in the CNS. 
 IL-23 is required for the development of pathogenic Th17 cells (McGeachy et al., 
2009), and the subunits of this interleukin (p40 and p19) have been detected in active 
lesions of patients (Li et al., 2007). In the EAE model, more severe disease was observed 
upon adoptive transfer of Th17 cells (Jager et al., 2009; Langrish et al., 2005), and 
neutralization of IL-17 ameliorated EAE (Hofstetter et al., 2005). Supporting a role for 
Th17 cells in multiple sclerosis, increased numbers of these cells have been detected in 
chronic MS lesions compared to acute lesions or to controls (no CNS pathology) (Lock et 
al., 2002), and IL-17 mRNA and protein in CD4 T cells were localized in active lesions 
and the borders of chronic lesions of MS patients (Tzartos et al., 2008).  
 However, once again despite supporting studies, the role of Th17 cells as the main 
effector cell of CNS immunity is not as clear-cut as it would seem. The effects of IL-23 
and IL-17 in EAE seem to be different: while IL-23 deficient mice were resistant to EAE, 
mice deficient in either IL-17A or F are still susceptible to disease. In these cases, disease 
was occasionally milder (Haak et al., 2009; Hofstetter et al., 2005), but this was not always 
the case (Langrish et al., 2005; Röhn et al., 2006). Furthermore, the distinction between 
Th1 and Th17 cells is not always defined; a degree of plasticity is present in their 
phenotype. There are Th cells which express both IFNγ and IL-17, in addition to the 
transcription factors T-bet and RORγt (Abromson-Leeman et al., 2009), and stimulation of 
Th17 cells with IL-12 (in the absence of TGF-β) promotes conversion to a Th1 phenotype 
as well as the production of IFNγ (Lee et al., 2009). In line with such plasticity, depending 
on the conditions, both Th1 and Th17 cells induce EAE (Kroenke et al., 2008; Stromnes et 
al., 2008). The resulting effects of each cell type is different: Th1-induced disease results 
in increased recruitment of macrophages, whereas disease mediated by Th17 promotes 
infiltration of neutrophils (Kroenke et al., 2008). Furthermore, the ratio of these cell types 
in passive EAE influenced localization of inflammation: a high Th17 to Th1 ratio in the 
brain meninges resulted in infiltration of the brain and the induction of inflammation 
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(Stromnes et al., 2008). Overall, it is clear that in spite of the evidence supporting a role for 
Th1 and Th17 cells in the pathogenesis of MS, further studies are most definitely required 
to more fully elucidate the roles each CD4 T cell subset plays in disease pathogenesis. 
Further adding to the complexity, the role of CD8 T cells in multiple sclerosis must also be 
considered. 
 The traditional culprits of multiple sclerosis pathology are indeed CD4 T cells 
(Delgado and Sheremata, 2006; Kuchroo et al., 2002; Steinman, 1996), but more recently, 
a role for CD8 T cells has been considered. Animal models of demyelinating and 
neurodegenerative disease have been shown to be mediated by CD8 T cells (Na et al., 
2008; Sanchez-Ruiz et al., 2008; Saxena et al., 2008); CD8 T cells have been detected in 
MS lesions in higher numbers than CD4 T cells (Babbe, 2000; Frischer et al., 2009; Hauser 
et al., 1986); there is clonal expansion and persistence of CD8 T cells within the CNS 
compartment of MS patients (Jacobsen, 2002; Junker et al., 2007; Skulina et al., 2004); and 
lastly, oligodendrocytes express MHC Class I, rendering them susceptible to direct attack 
by activated CD8 T cells (Ruijs et al., 1990). Furthermore, the fact that CD8 T cells 
recognize MHC class I, expressed by all cells, and mediate the direct killing of cells 
implies a direct role in causing the damage seen in the CNS. 
 CD8 T cells have three effector pathways through which they can mediate cell-
killing via apoptosis: one is secretion of cytotoxic granules containing perforin and serine 
proteases (Kierdorf et al., 2010); the second is the interaction between CD95 on the CTLs 
interacting with CD95L on the target cell after Ag-MHC I recognition (Siegel et al., 2000); 
and lastly there is the secretion of cytokines belonging to the TNF family, where TNFα 
binding to its receptor activates the receptor death domain. However, to be able to mediate 
killing, CD8 T cells must recognize their Ag-MHC I complex. The challenge is that 
classical MHC class I molecules are not constitutively expressed on all neural cells, and so 
are not efficient at activating CD8 T cells. However MHC expression is induced on neural 
cells during most inflammatory and degenerative CNS diseases (Neumann et al., 2002): 
astrocytes, oligodendrocytes , neurons and axons in acute MS lesions upregulate the 
expression of MHC class I (Hoftberger et al., 2004), and thus are rendered susceptible to 
killing by activated CD8 T cells.  
 Primary cultures of microglia are inefficient at MHC class I presentation, but they 
are lysed when CTLs recognize their antigen-MHC combination (Bergmann et al., 1999). 
 46
CNS-invading CTLs activated in the periphery release proinflammatory cytokines (IFNγ 
and TNFα) which can induce expression of MHC on brain cells in vitro (Vass and 
Lassmann, 1990). MHC class I expression on astrocytes is upregulated by IFNγ, and are 
susceptible to lysis by CTLs via a granule mechanism, or via CD95/Fas-mediated 
apoptosis (Medana et al., 2001a). While oligodendrocytes express MHC I, they lack 
expression of co-stimulatory molecules; however, upon treatment with IFNγ, they express 
CD95 and are thus susceptible to apoptosis (Pouly et al., 2000). Lastly, there are the 
neurons. The expression of MHC I on neurons is more strictly regulated than in other cell 
types (Neumann, 2001), but “electrically silent” neurons do express MHC I (Neumann et 
al., 1995), and, as in the other neural cells, after IFNγ treatment they express MHC I 
(Neumann et al., 1997; Rensing-Ehl et al., 1996). CTL form stable contacts with neurites 
in culture suggesting they directly cause axonal damage in vivo (Medana et al., 2001b). 
   
3.2.2.3 MS and inflammation: the role of B cells 
 Many lines of evidence exist for the involvement of B cells in the pathogenesis of 
multiple sclerosis. However, it has taken longer for the participation of B cells to be 
identified, perhaps due to the lack of their contribution in “traditional” EAE models 
(Batoulis et al., 2010). EAE models using proteins rather than the usual relatively short 
peptide sequences (Figueiredo et al., 1999; Kuerten et al., 2006; Lyons et al., 1999) have 
demonstrated a role for B cells in disease pathology. Further supporting a role for B cells, 
while the passive transfer of myelin-specific antibodies did not induce EAE, the depletion 
of B cells created resistance to active EAE (Batoulis et al., 2010). Finally, the transfer of 
MOG-primed serum into B cell deficient hosts resulted in a disease course similar to that 
seen in wild-type hosts (Lyons et al., 2002). 
 In multiple sclerosis, the role B cells play in CNS inflammation and modulating the 
disease course can perhaps best be indicated by the effects of treatment targeting B cells in 
MS. Patients treated with anti-CD20 Ab (rituximab), an antibody depleting B cells but not 
plasma cells and therefore not impacting antibody production, showed a reduction in 
gadolinium-enhancing brain lesions (Bar-Or et al., 2008; Hauser et al., 2008) as well as in 
the B cells found in CSF (Cross et al., 2006). 
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 Plasma cells, myelin-specific antibodies and even B cells have been found in MS 
lesions (Cross and Waubant, 2011). Higher concentrations of IgG antibody displaying 
oligoclonal bands, is found in the brain and CSF of patients with MS as compared to 
controls (Hemmer et al., 2002). In addition, IgG has been observed within myelin in MS 
lesions and in macrophages containing myelin debris (Barnett et al., 2009); however, this 
was not specific to MS and seems to be associated with damage to white matter in general 
(Barnett et al., 2009). Antibody extracted from MS CNS tissue has been demonstrated to 
be reactive to myelin proteins. IgG isolated from MS plaques are specific for MBP 
(Warren and Catz, 1993; Wucherpfennig et al., 1997) and MOG (O’Connor et al., 2005). 
 Antibody-secreting B cells are present in MS lesions and CSF, and are clonally 
expanded (Baranzini, 1999; Colombo, 2000); furthermore, the heavy chains identified in 
MS plaques were not observed in the peripheral blood (Owens et al., 2001). B cell follicle-
like structures have been identified in the meninges of patients with secondary progressive 
MS (Magliozzi et al., 2007; Serafini et al., 2004), and in some cases, their presence has 
been identified with a more aggressive clinical course (Magliozzi et al., 2007). This 
implies an environment within the CNS promoting B cell expansion and antibody 
production can exist (Cross and Waubant, 2011). Indeed, these follicles contain not only B 
cells, but also T cells, plasma cells and follicular DCs which produce chemokines such as 
CXCL13 (Serafini et al., 2004). CXCL13 is a B cell-attracting chemokine, and plays a 
crucial role in germinal center organization and the recruitment of B cells into lymphoid 
tissue (Reindl et al., 2010). However, other groups have not detected meningeal B cell 
follicles in MS (Peferoen et al., 2010; Willis et al., 2009) 
 
3.3 Therapies 
 Treatments for multiple sclerosis are only partially effective. What remains a 
challenge is the inability of treatments to cross the BBB and enter the CNS, where 
activated immune cells are found; however, current treatments do have a degree of efficacy 
although the side effects, since they affect the immune system function, can be severe. 
While effective to a degree, there still is a need to develop alternative strategies that have 
more of an impact on ameliorating the disease course, and that are administered differently 
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such as fingolimod (FTY-20), which is administered orally, rather than current treatments 
which involve multiple injections. 
IFNβ: IFNβ is an immunomodulator injected intramuscularly (weekly) or subcutaneously 
(three times weekly) (Cohen and Rieckmann, 2007), that decreases numerous immune 
responses. It inhibits adhesion of cells, as well as the synthesis and transport of matrix 
metalloproteinases which have a role in breaking down the integrity of the BBB (Frohman 
et al., 2006). IFNβ also has the ability to reduce MHC class II expression on B cells and 
their ability to present antigen to T cells (Boster et al., 2010). 
Glatiramer Acetate: Glatiramer acetate (GA) is a random polymer of four amino acids. It is 
administered daily, subcutaneously (Cohen and Rieckmann, 2007) and used to treat 
patients with RRMS (Frohman et al., 2006). It is thought that GA can induce a shift in the 
activation state of T cells in the periphery from a Th1 to a Th2 phenotype (Boster et al., 
2010), increasing regulatory T cell levels and suppressing inflammatory cytokines 
(Frohman et al., 2006). It has also been shown to modulate APC function by blocking 
antigen presentation (Boster et al., 2010; Frohman et al., 2006).   
Natalizumab: This drug was initially developed to inhibit T cell adhesion to the inflamed 
endothelium in EAE; it is a monoclonal antibody that blocks α4 integrins. It is given to 
patients intravenously on a monthly basis (Cohen and Rieckmann, 2007). Studies have 
shown that natalizumab impairs CNS immune surveillance, inhibiting lymphocyte entry in 
the subarachnoid space. While it has been effective in treating MS patients, potential side 
effects can be severe, with a fraction of patients treated with natalizumab developing 
progressive multifocal leukoencephalopathy induced by virus infecting oligodendrocytes 
(Boster et al., 2010). 
Mitoxantrone: Mitoxantrone is a chemotherapeutic agent, administered intravenously 
every three months (Cohen and Rieckmann, 2007). It is used short-term in patients with 
RRMS or SPMS prior to switching them to other, less severe therapies (Boster et al., 2010; 
Frohman et al., 2006). It reduces levels of Th1 cytokines such as lymphotoxin and TNFα 
and suppresses proliferation of T cells, B cells and macrophages (Boster et al., 2010).  
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Rituximab: Therapy with rituximab, a monoclonal antibody, results in a depletion of the 
CD20+ B cell population (Boster et al., 2010) without affecting the Ab-producing plasma 
cells. Treatment with this drug resulted in a significant reduction in gadolinium-enhancing 
lesions in RRMS patients (Boster et al., 2010; Hauser et al., 2008). Studies indicate that B 
cell depletion leading to diminished proinflammatory responses by CD4 and CD8 T cells is 
effective due to the removal of cytokines produced and expressed by B cells (Bar-Or et al., 
2010). This drug is not yet approved, and is still in clinical trials. 
Fingolimod (FTY): FTY belongs to a new class of drugs in the treatment of MS; it is 
administered orally rather than via injection and has been recently approved by the FDA 
and in Canada. It is a sphingosine-1-phosphate (S1P) receptor agonist; S1P is a G protein-
coupled receptor ligand playing a role in the migration of lymphocytes through secondary 
lymphoid organs. Treatment with FTY results in a dose-dependent reversible decrease in 
peripheral blood lymphocyte counts. Peripheral counts decrease due to the fact B and T 
lymphocytes are sequestered in secondary lymphoid organs (Brown et al., 2007).  
 
However, while these various treatments can ameliorate the course and severity of disease, 
none of them actually cure MS, and so the development of new therapies is crucial.
 50
 
 
 
 
 
 
 
 
 
 
 
HYPOTHESIS AND OBJECTIVES 
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 RATIONALE 
In our laboratory, we study various factors influencing the activation state of CD8 T cells, 
in the context of MS; one such factor we have selected to study is interleukin-15. This is a 
cytokine that plays a central role in immunity and is involved in enhancing CD8 T cell 
activation and proliferation. IL-15 has been shown to be up-regulated in the blood and CSF 
of MS patients, and our laboratory has demonstrated IL-15 to be up-regulated in MS brain 
lesions, as well as in the blood of MS patients as compared to healthy controls (Saikali et 
al., 2010; Schneider et al., in press). Furthermore, we observed that CD8 T cells from MS 
patients are activated to a greater degree upon the addition of recombinant IL-15 in culture 
relative to healthy controls and display an enhanced cytotoxic profile. We also observed 
elevated proportions of B cells from MS patients expressing IL-15 as compared to 
controls. Considering that IL-15 has been previously mainly described on 
macrophages/monocytes, we investigated the role of IL-15 expressed by B cells. In 
addition to this, to work towards understanding the role of IL-15 in disease pathogenesis, 
we examined the expression of IL-15 in mouse models for MS: EAE.  
 
We hypothesize that peripheral sources of IL-15 contribute to the enhancement of CD8 
T cell responses in MS patients, and that IL-15 provided by the inflamed CNS actively 
contributes to enhancing CD8 T cell responses. 
 
Objectives: 
1. To assess surface IL-15 and IL-15Rα expression on human B lymphocytes and to 
determine whether expression levels are sufficient to enhance human CD8 T cell 
functions; and 
2. To assess and establish the in vivo expression of IL-15 in MS mouse models.
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MATERIALS AND METHODS 
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1.0 ISOLATION OF HUMAN BLOOD CELLS 
1.1 Isolation of peripheral mononuclear cells (PBMC) from human blood 
 One hundred  mL of blood was collected from healthy consenting donors in 10 cc 
tubes (VACUTAINER®; Becton Dickinson, Oakville, ON, Canada) treated with 
ethylenediaminetetraacetic acid (EDTA) in accordance with the local ethical committee 
(HD 07.002 and BH 07.001). Around 20 mL of blood was transferred into individual 
50mL conical tubes and diluted with PBS-EDTA (2mM EDTA) for a final volume of 35 
mL of diluted blood. Fourteen mL of Ficoll-PaqueTM PLUS (GE Healthcare Bio-Sciences 
AB, Uppsala, Sweden) was under-laid to form a distinct layer below the diluted blood. 
Tubes were then centrifuged for 30 minutes at 851 x g at room temperature (RT) without 
brakes. The top layer consisting of serum was removed, and the PBMC layer collected and 
transferred into a fresh 50 mL tube, then washed with PBS-EDTA and centrifuged at 479  
x g for 15 minutes. The supernatant was discarded, the pellet re-suspended and washed 
twice more with PBS-EDTA (10 minutes per wash at 417 x g). Cells from the same donor 
were pooled and passed through a 70μm nylon mesh (BD Biosciences, Mississauga, ON, 
Canada) and counted using a hemacytometer before the second wash. Finally, cells were 
re-suspended in cold MACS buffer (PBS containing 2mM EDTA and 0.5% (v/v) Fetal 
Bovine Serum (FBS), Wisent) for isolation of specific subpopulations. 
1.2 Isolation of CD8 T cells and B cells 
 CD8 T cells and B cells were isolated using positive selection. After isolation of 
PBMC, cell pellet was resuspended in 90 μL of MACS buffer per 107 total cells and 10 μL 
of CD8+ or CD19+ (CD8 T or B cell isolation respectively) MicroBeads (Miltenyi Biotech 
Inc., Auburn, CA, USA) were added per 107 total cells, and incubated for 15 minutes at 
4oC. After incubation, cells were washed in 2 mL buffer per 107 cells and centrifuged at 
417 x g for 10 minutes. Supernatant was removed, and up to 108 cells resuspended in 500 
μL of buffer. Magnetic separation was carried out using LS MACS Columns (Miltenyi 
Biotech Inc.); column was placed in MACS Separator, and rinsed with 3 mL of MACS 
buffer. Cell suspension was then applied to the column; column was washed three times 
with 3 mL of buffer per wash; flow-through with unlabelled cell fraction was collected in 
15 mL conical tubes. After the washes, column was removed from the separator and 
positively-labelled cells flushed out with 5 mL of buffer.  Cells were counted, washed and 
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re-suspended in appropriate medium. Purity assessed by flow cytometry of isolated cell 
populations was >95%. 
2.0 IN-VITRO ASSAYS 
2.1 Upregulation of IL-15 on B cells 
 For the TLR stimulation assay, LPS from Escherichia coli serotype 0127:B8 
(Sigma-Aldrich, Oakville, ON, Canada) (100pg/ml), or CpG oligonucleotide (CpG); 
Invivogen) (18µg/ml) was used as ligands for TLR4 and 9 respectively. Recombinant 
human high-mobility group protein B1 (HMGB1; R&D Systems, Minneapolis, MN) 
(2µg/ml) was also used as a ligand for TLR4. The BCR was stimulated using F(ab’)2 
fragment goat anti-human Ig (αhu Ig; Jackson ImmunoResearch Laboratories, West 
Grove, PA) (2.5µg/ml). B cells were co-cultured with one of the above stimuli for 4 days. 
B cells were then harvested and labeled for flow cytometry analysis or used as antigen 
presenting cells (APC) in co-culture with T cells. 
 Isolated human B cells were co-cultured with either irradiated NIH-3T3 cells 
expressing CD40L or with irradiated control NIH-3T3 cells, in the presence of IL-4. 3T3 
cultures at 70-90% confluence were washed with PBS, trypsinated at room temperature 
with trypsin (0.25%) (Wisent) diluted in PBS, and washed in R10 (RPMI 1640 (Roswell 
Park Memorial Institute medium), 100 IU/mL Penicillin, 100 μg/mL Streptomycin, 10 % 
(v/v FBS,  and 2mM L-glutamine; Wisent) after 2 minutes. 3T3 cells were then 
resuspended in Iscove's Modified Dulbecco's Medium (IMDM) supplemented with 
Penicillin (100 IU/mL), Streptomycin (100 μg/mL), 10 % FBS and L-glutamine (2mM) to 
a concentration of 5x105 cells/mL. 3T3 cells were then irradiated (1500 rad) and then 
plated in 6-well plates, at 5x105 cells/well and incubated for at least 30 minutes to allow 
the 3T3s to adhere to the well bottoms. One million isolated human B cells were added to 
the 3T3 cells, and IL-4 was added (10 ng/mL) to promote cell-survival in a final volume of 
3 mL. Kinetics to determine the optimal number of days was carried out. B cells were 
harvested after 2, 3, or 4 days and surface expression of IL-15 examined using flow 
cytometry. For subsequent experiments, B cells were incubated with 3T3 cells for 4 days 
prior to flow cytometry analysis.  
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2.2 CFSE labelling of CD8 T cells 
 After isolation, CD8 T cells were resuspended in RPMI (Wisent) without serum, 
pre-warmed to 37oC at > 5x106 cells/mL. CFSE (5,6- carboxyfluorescein succinimidyl 
ester, Molecular Probes) was added at 1.25 μM and incubated for 10 minutes at 37oC. Dye 
was quenched with FBS at room temperature for 5 minutes, then washed twice with RPMI 
for 10 minutes at 423 x g. Lastly, cells were resuspended in R10 and counted. 
2.3 CD8 T cell and B cell co-cultures 
 48-well plates were coated with α-CD3 (clone OKT3, 32.5 ng/ml) overnight. B 
cells activated with CD40L were harvested, washed in R10 medium and counted. Up to 
7x106 B cells from each donor were resuspended in 2 mL of R10 and Fc receptors blocked 
for 20 min with normal mouse immunoglobulin (msIgG; invitrogen); cells were 
subsequently divided into two parts: one half was incubated 1h with msIgG (10 μg/mL), 
and the other was incubated with a blocking mouse anti-human antibody (Ab) specific to 
IL-15 (10 μg/mL; R&D Systems) for 1h. While blocking, CD8 T cells were labelled with 
CFSE and then added onto α-CD3-coated plates for at least half an hour at 5x105 
cells/well. After blocking, R10 was added to B cells to a final concentration of 2x105 
cells/mL, and 500 μL of the cell suspension was added to the CFSE-labelled CD8 T cells. 
B cell-CD8 T cell co-cultures were incubated for 6 days at 37oC, then harvested and 
stained for flow cytometry. 
2.4 Flow Cytometry 
 Stainings were performed in a V-bottom 96-well plate, using the antibodies listed 
in Table 1. Staining B cells for surface IL-15, cells were blocked with mouse IgG for 20 
min on ice in FACS buffer, washed and then followed by surface staining. For surface 
stainings, cells were incubated with relevant antibodies for at least 20 min on ice, or 
overnight at 4oC, in FACS buffer (PBS, 1% (v/v) FBS and 0.1% (w/v) NaN3) in a total 
volume of 50 μL. Unbound antibodies were removed by washing twice in the same buffer.  
To measure interferon-γ and granzyme B (intracellular), after 6 days in culture, CD8 T-B 
cell co-cultures were stimulated for 4-5 hours with PMA (1μg/mL), ionomycin (20 ng/mL) 
and Brefeldin A (5 μg/mL), then stained for surface markers before fixation in 
paraformaldehyde (PFA)-saponin buffer (Hank’s Balanced Salt Solution (HBSS; Wisent), 
containing 4% (w/v) PFA (Sigma-Aldrich), 1mM HEPES (Wisent) and 0.1% (w/v) 
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saponin from Quilla JA Bark, Sigma-Aldrich) at room temperature (RT) for 10 minutes 
followed by two washes in saponin buffer (PBS, 0.1% (w/v) saponin, 1% (v/v) FBS and 
0.1% (w/v) NaN3). Intracellular staining was performed in saponin buffer for 30 minutes. 
Isotype staining was performed using the corresponding Ab at the same concentration as 
the staining Ab. After surface staining, cells were resuspended in 200 μL 1% 
formaldehyde; cells stained intracellularly were resuspended in 200 μL of FACS buffer. A 
FACS LSR II (BD Biosciences) was used for acquisition, and results were analyzed using 
FlowJo software (Treestar, San Carlos, CA).  
Table 1. Antibodies used for flow cytometry analysis 
Antibody Conjugate* Concentration per stain Isotype Distributor+ 
Primary: targeting mouse     
CD3e PerCP-Cy5.5 200 μg/mL 0.1 μg Hamster IgG1 BD  
CD4 A700 200 μg/mL 0.01 μg Rat IgG2a BD  
CD8a PB 200 μg/mL 0.04 μg Rat(Lou) IgG2a BD  
CD122 PE 200 μg/mL 0.06 μg Rat IgG2b Cedarlane 
IL-15  500 μg/mL 2.5 μg Rabbit IgG Cedarlane 
IL-15Rα (biotin) 50 μg/mL 0.25 μg Gt IgG Cedarlane 
CD45 PECy7 200 μg/mL 0.1 μg Rat IgG2b BD  
B220  A488 200 μg/mL 0.1 μg Rat IgG2a Cedarlane 
CD11b A700 200 μg/mL 0.1 μg Rat IgG2b Cedarlane 
Primary: targeting human     
CD20 PECy7 0.2 mg/mL 0.8 μg ms IgG1 BD  
CD86 allophycocyanin 3 μg/mL 0.015 μg ms IgG1 BD  
HLA-DR A700 unknown 5 μL ms IgG2b Cedarlane 
IL-15 PECy7 25 μg/mL 0.25 μg ms IgG1 Cedarlane 
IL-15Rα (biotin) 0.5 mg/mL 0.5 μg ms IgG2b Cedarlane 
CD8 PB 0.2 mg/mL 0.1 μg ms IgG1 BD  
Granzyme B allophycocyanin unknown 0.2 μL ms IgG1 Invitrogen 
Interferon-γ A700 0.2 mg/mL 0.04 μg ms IgG1 BD  
Secondary      
Streptavidin allophycocyanin 0.2 mg/mL 0.1 μg  BD  
Streptavidin PerCPCy5.5 0.2 mg/mL 0.1 μg  Cedarlane 
Gt α-Rabbit A488 2 mg/mL 1 μg  Invitrogen 
Gt α-Rabbit PE 500 μg/mL 0.25 μg  Cedarlane 
Other      
LIVE/DEAD®-
Fixable Dead Cell 
Stain Kit 
aqua fluorescent 
reactive dye 
unknown 0.5 μL  Invitrogen 
*Abbreviations (fluorochromes): A488, Alexa Fluor® 488; A700, Alexa Fluor® 700; PB, Pacific Blue; PerCP-Cy5.5, 
Peridinin-chlorophyll proteins-Cy5.5; PE, Phycoerythrin; PECy7, Phycoerythrin-Cy7. +BD,  BD Biosciences. 
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2.5 Isolation of Human Brain Endothelial Cell (HBEC)* and Migration Assay 
(*procedure performed by the team of Dr. Alexandre Prat, our collaborator)  
 HBECs were isolated from CNS tissue specimens of temporal lobe resections from 
young adults undergoing surgery for intractable epilepsy, as previously described (Prat et 
al., 2000b). Prior to surgery, ethical approval and informed consent were given (BH 
07.001). HBECs were isolated from non-epileptic material to generate an in vitro model of 
the human BBB according to a published protocol (Prat et al., 2000b).  
 Migration assays were performed in a modified Boyden chamber as previously 
described (Prat et al., 2000b). HBECs plated on Boyden chambers (Collaborative 
Biomedical Products, Bedford, MA) were stimulated with IFN-γ (200U/ml) and TNF 
(200U/ml) for 24 hours. B cells were activated with CD40L-expressing 3T3 cells as 
described above, and subsequently cultured with CD8 T cells, in the presence of α-CD3. 
After 6 days, CD8 T cells were harvested by magnetic bead separation as previously 
described and added to the upper chamber and allowed to migrate for 18h across pre-
activated HBECs. The ability of CD8 T cells to cross the HBEC-monolayer was assessed 
by counting the absolute number of cells in triplicate wells that migrated to the lower 
chamber after 18h. 
3.0 IL-15 AND EAE 
3.1 Induction of Active Experimental Autoimmune Encephalomyelitis 
 Experimental autoimmune encephalomyelitis (EAE) was induced in 6-7 wk old 
female SJL/J (SJL) and C57BL/6 (B6) mice via subcutaneous injections of emulsions 
containing myelin peptide and intraperitoneal injections of pertusis toxin. Mice were 
shaved at the injection site (at the base of the tail) at least two days in advance. To prepare 
the emulsions, Mycobacterium tuberculosis was added to Incomplete Freund’s adjuvant 
(DIFCO) to make Complete Freund’s adjuvant (CFA), and was used at a concentration of 
8mg/mL M. tuberculosis. Proteolipid protein 139-151 (PLP139-151; Alpha Diagnostic) was 
used at a concentration of 3 mg/mL in PBS, and myelin oligodendrocyte glycoprotein 35-
55 (MOG35-55; Alpha Diagnostic) was used at 4 mg/mL in PBS. Emulsions were made by 
mixing equal parts of CFA and peptide by passing solutions through a micro-emulsifying 
needle (Fisher Scientific), and subsequently injected subcutaneously (2 injections of 50 μL 
on each side) near the base of the tail of SJL or B6 mice using PLP139-151 (150 μg/mouse) 
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or MOG35-55 ( 200 μg/mouse) peptide, respectively. Pertussis toxin (Cedarlane 
Laboratories) was injected at day 0 with the emulsions, and again at day 2:  Lyophilised 
toxin was resuspended in HBSS to a concentration of 50 μg/mL, and 100 μL at 4 μg/mL 
(400 ng) was injected intraperitoneally.  
3.2 Scoring 
 Mice were weighed and scored daily from day 7-8 post-injection. Scores were 
given using the criteria shown in table 2. Animals were sacrificed if reaching 20% weight 
loss or score of 4.0-4.5.  
Table 2. Disease scores for mice with EAE 
Score Symptoms 
0.5 tail does not wrap around cylindrical object 
1.0 limp tail 
1.5 limp tail, mild ataxia 
2.0 limp tail, ataxia 
2.5 ataxia and weakness in hind limbs (weak grip) 
3.0 one hind limb paralyzed 
3.5 one hind limb paralyzed, weakness in other 
4.0 both hind limbs paralyzed 
4.5 both hind limbs paralyzed, weakness in forelimbs 
5.0 Moribund 
 
3.3 Perfusion 
 Mice were anesthetized using isofluorane. Once they were no longer responsive to 
toe-pinching, they were immobilized using pins on a styrofoam board. Thoracic cage was 
opened and heart exposed. A small incision was made in the lower right side, and a 26G 
needle connected to a pump with PBS was inserted into the left-hand side. Mice were 
perfused with around 25 mL of saline, until PBS flowing out of heart was clear. 
3.4 Processing of organs: Lymphocyte isolation 
 Spleen: spleen was harvested and put in 5 mL R10 on ice. Spleens were mashed 
through a cell strainer (70 μm, BD Biosciences) in a Petri dish to make a single cell 
suspension. Cell strainer and Petri dishes were rinsed with RPMI. Cells were centrifuged at 
424 x g for 7 min. Supernatant was poured off, and cells resuspended. One mL of 0.83% 
(w/v) ammonium chloride was added per spleen, tubes inverted to mix, and incubated at 
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RT for 4 min. Medium was added to >10 mL, and centrifuged at 424 x g for 7 min. Cells 
were then resuspended, passed through a cell strainer again to remove debris, and re-
centrifuged at same speed. Cells were finally resuspended and counted. Cell concentration 
was adjusted to 1 x 107 cells/mL in R10 (for culture) or FACS buffer (for staining). 
 Draining lymph nodes: Inguinal lymph nodes, which drained the injection sites, 
were collected in 5 mL R10 on ice, mashed through a cell strainer. Filter and Petri dishes 
rinsed with RPMI, cells collected and centrifuged at 424 x g for 7 min. Supernatant was 
removed and then cells resuspended and counted. Cell concentration was adjusted to 1 x 
107 cells/mL in R10 (for culture) or FACS buffer (for staining). 
 CNS: brain and spinal cord were collected in ice-cold R10, and mashed through a 
cell strainer (70 μm). Cells were passed multiple times through strainer to homogenize. 
Strainer and Petri dish washed with RPMI to a final volume of 15 mL. Homogenates were 
centrifuged at 400 x g at 40C for 7 min. Supernatants carefully poured off, pellets 
resuspended in 4 mL 90% Percoll (VWR) solution. 3 mL of 60% Percoll was carefully 
added on top of 90% layer, followed by a 40% Percoll layer (4 mL) and 2-3 mL HBSS 
(1x) to make a total volume of 14.5 mL. Discontinuous gradients were centrifuged at 40C 
at 1000 x g for 15 min, without brakes. Myelin layer (0-40% interface) was discarded; 
liquid was collected until 60-90% interface (5-6 mL left in tube) and transferred to a fresh 
tube. Percoll was washed by adding HBSS to collected fraction and centrifuged for 10 min 
at 424 x g at 40C. Supernatant was removed, pellet resuspended and washed again in RPMI 
for 10 min at 424 x g. Supernatant was removed and pellet resuspended in 400 μL R10 or 
FACS buffer. 
 
4.0 IL-15 EXPRESSION: QUANTITATIVE (REAL-TIME) PCR 
4.1 RNA extraction: B cells 
 Cellular RNA was extracted using the RNeasy Mini Kit (Qiagen, Mississauga, On, 
Canada) according to manufacturer’s instructions. Briefly, isolated human B cells were 
disrupted through the addition of RLT buffer and the lysate passed through a 1 mL RNase-
free syringe (BD Bicosciences) with a 20-gauge needle. 70% Ethanol was added at an 
equivalent volume to the homogenized lysate, and mixed by pipetting up and down. Up to 
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700 μL of sample were transferred to a RNase-free spin column with a collection tube 
(provided in the kit), and centrifuged at 8000 x g for 15s. The process was repeated for 
samples at volumes greater than 700 μL.  Flow-through was discarded, and the spin 
column membrane washed with 700 μL of Buffer RW1 for 15s at 8000 x g, followed by 
two washes using RPE buffer (500 μL for 15s at 8000xg, second wash for 2 min). 
Columns were then transferred to new collection tubes and centrifuged at full speed for 1 
min. To elute the RNA, spin columns were transferred to 1.5 mL RNase-free Eppendorf 
tubes, 30-50 μL of RNase-free water added directly to the membrane, and centrifuged for 1 
min at 8000 x g. RNA concentration and purity were determined using a nanodrop. RNA 
was then stored at -80oC or immediately followed by cDNA transcription. 260/280 nm 
ratio was typically > 1.8.   
4.2 RNA extraction: Mouse tissue 
 Liver, spleen, cortex, brain stem, and spinal cord were collected and put into Trizol 
(50-100 mg tissue/mL trizol; Invitrogen). Tissue was homogenized using a polytron and 
then placed at -800C. To extract RNA, tissue samples were defrosted at RT. 200 μL 
chloroform was added  per mL trizol; sample was vortexed for 15 sec and then incubated 
2-3 min at RT. Samples were then centrifuged for 15 min at 12 000 x g at 40C. The 
aqueous phase was transferred into fresh tubes, and 0.5mL isopropanol/1 mL trizol used 
was added, and incubated for 10min at RT. Samples were centrifuged again at the same 
speed and temperature, for 10 min. Supernatant was removed and pellet washed with 1 mL 
75% ethanol/1 mL trizol used. Samples were vortexed and subsequently centrifuged at 
7500 x g for 5 min at 40C. Ethanol was removed, and RNA left to dry until transparent. 
RNA was then resuspended in either 50 μL (spinal cord) or 100 μL (all other tissues) 
RNase free water. RNA concentration and purity was determined using a NanoDrop 
(Thermo Scientific, Wilmington, DE, USA). 260/280 nm ration was typically >1.8. RNA 
aliquots were adjusted to 1 mg/mL where possible, and stored at -800C.  
4.3 Complementary DNA (cDNA) 
 The QuantiTect Reverse Transcription Kit (Qiagen) was used for cDNA synthesis, 
following manufacturer’s instructions. Potentially contaminating genomic DNA was 
eliminated using gDNA Wipeout Buffer, incubated with total RNA at 42oC for 2 min. 
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RNA was then transcribed into cDNA using a master mix prepared from Quantiscript 
Reverse Transcriptase, Quantiscript RT Buffer, and RT Primer Mix; the reaction was 
incubated at 42oC for 30 min, and then at 95o for 3 min to inactivate the reverse 
transcriptase. RNase inhibitor and dNTPs were present in the kit components. 
4.4 Quantitative/Real-time Polymerase Chain Reaction 
 B cells: qPCR was used to examine the up-reguation of human IL-15 and IL-15Rα 
upon activation via CD40L/CD40. Relative gene expression was determined using primers 
and TaqMan FAM-labeled MGB probes for human IL-15 and IL-15Rα and ribosomal 18S 
(VIC-labeled probe, used as an endogenous control) (Applied Biosystems, Foster City, 
CA) and according to the manufacturer’s instructions. 
 Mice: The expression of IL-15 in various tissues at various points of disease was 
determined using qPCR. Spleen and liver were used as controls for mouse IL-15 
expression. Tissue from the CNS was divided into: the cortex, brain stem, and spinal cord. 
Tissue was also taken from control mice which had either been injected with an emulsion 
of CFA and PBS (no peptide), or had not been injected. IL-15 expression was examined at 
onset and peak of disease (SJL mice) or at onset, peak and remission (B6 mice). Relative 
gene expression was determined using primers and TaqMan VIC-labeled probes for IL-15 
and Hprt1 (hypoxanthine phosphoribosyltransferase 1; VIC-labeled probe, used as an 
endogenous control) (Applied Biosystems, Foster City, CA) and according to the 
manufacturer’s instructions. 
 
 For all PCR reactions, RNAse-free water was used as a negative control. Each 
sample was run in triplicate, in a volume of 10uL in a 384-well plate. Plate was spun at 
high speed for several seconds to ensure air bubbles were removed. Plates were incubated 
in a 7900 Fast Real Time PCR system (Applied Biosystems) for 10 min at 950C, This was 
followed by 40 cycles of PCR: denaturation of cDNA at 950C for 15 sec, and followed by 
synthesis of a new DNA strand at 600C for 1 min. The threshold fluoresence (the point at 
which an increase in fluorescence is distinguishable from the background) and the CT 
readout (the point at which the detected signal is significantly above threshold) were 
automatically determined by the Sequence Detection System (SDS) software.  
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The relative expression of each gene was compared to either 18S (human cells) or 
Hprt1 (murine cells) and calculated as ΔCT, the difference in threshold cycles for target and 
reference genes using the following formula: ΔCT=CT(target)-CT(reference). Finally, the levels of 
the target gene expressed were normalized to the endogenous reference, and calculated as 
2^(-ΔCT).  
5.0 STATISTICAL ANALYSIS  
 Data were analyzed using GraphPad Prism software (San Diego, CA). Statistical 
analyses include paired student’s t test.
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1.0 B CELL ACTIVATION AND IL-15 PRODUCTION 
1.1 Optimizing IL-15 production by B cells 
 Our laboratory observed increased proportions of monocytes/macrophages and B 
cells carrying IL-15 in multiple sclerosis compared to controls (Schneider et al. in press 
2011), with the former cell type expressing higher levels of the cytokine (Schneider et al. 
in press 2011). The expression of IL-15 on monocytes/macrophages in the context of MS 
has already been described (Vaknin-Dembinsky et al., 2008) thus we focused on the 
expression of IL-15 on B cells. Cytokine expression by B cells in the context of MS is also 
of interest due to the efficacy of the drug Rituximab, which depletes the CD20+ B cell 
population; its efficacy is thought to be due to the removal of cytokines produced and 
expressed by B cells (Bar-Or et al., 2010). IL-15 could be one such cytokine. And so, we 
decided to test various stimuli for their capacity to activate B cells and potentially induce 
an increase in surface IL-15 on B cells. We measured expression of surface IL-15 as the 
IL-15Rα binds its cytokine with high-affinity, and so IL-15 is essentially presented on the 
cell surface rather than secreted (Fehniger and Caliguri, 2001). 
 CD40L as a stimulus is of interest: its use as an activator of B cells has already 
been previously described (Arbour et al., 2006; Banchereau et al., 1991; Lapointe et al., 
2003), and CD40L expression has been reported to be up-regulated  in various 
autoimmune disorders including MS (Gerritse et al., 1996a; Peters et al., 2009a; Teleshova 
et al., 2000). In addition to stimulation using CD40L, there is an increasing interest in the 
role of Toll-like Receptors (TLRs) in the development of autoimmunity (Green and 
Marshak-Rothstein, 2011; Horton et al., 2010; Reynolds et al., 2010) and their role in MS 
or EAE are under investigation (Carty and Bowie, 2011; Marta et al., 2009; Smolianov et 
al., 2011). TLRs can either exacerbate or suppress CNS inflammatory demyelination, 
depending on the stimulus and hence which TLR is being stimulated (Brien and Gran, 
2008). Stimulation of the BCR is achieved via cross-linking of the receptor, and results in 
down-stream signaling and the production of various factors, including cytokines.  
We assessed the ability of various stimuli to enhance the surface expression of IL-
15 on B cells: HMGB1, LPS, and CpG were used to stimulate TLRs 2, 4 and 9; NIH-3T3  
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Fig.3: CD40L is a potent stimulus for the upregulation of IL-15 on B cells. B cells were cultured for 
3-4 days in the presence of different stimuli, after which they were harvested, stained and assessed for 
IL-15 and IL-15Rα surface expression by flow cytometry. (A) Representative FACS plots of B cells 
cultured in the presence of various stimuli as indicated above each plot. No significant upregulation of 
IL-15 and its receptor was observed  via TLR (LPS, CpG, HMGB1) or BCR (αhu Ig) stimulation. 
However, IL-15 and IL-15Rα were significantly upregulated via stimulation of CD40 on B cells. 
Fluoresence minus one controls for activation with CD40L shown in right panel. (B) HLA-DR and 
CD40 were assessed on the same cells; expression was increased upon stimulation with CpG, LPS, and 
αhuIg. Activation was not necessarily correlated with IL-15 expression. (C) Left panel: Pooled data 
showing proportion of B cells expressing IL-15 and IL-15 Rα after culture. Right panel shows 
difference in median fluoresence intensity (ΔMFI) of IL-15 expression on the same cells. (n=5). Cells 
were gated on living CD20+ B cells. No stimulus indicated by “nil”. Statistics: student’s t test, * p<0.05, 
**p<0.01.
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human Ig was used to stimulate the BCR as previously demonstrated by others (Pittner and 
Snow, 1998). B cells were isolated from PBMCs obtained from healthy donors using 
CD19+ positive selection; purity was typically over 95%. B cells were put in culture for 4 
days and then analyzed by flow cytometry, gating on CD20+ living cells as determined by 
LIVE/DEAD staining. Untreated B cells were used as control. Representative FACS plots 
of IL-15 and IL-15Rα up-regulation are shown in Fig. 3A. Stimulation using LPS, CpG, 
HMGB1 or αhu Ig did not lead to a significant up-regulation of surface IL-15 (Fig. 3C, 
pooled data from n=4-8 tested donors). However, while there was no change in cytokine 
levels, this was not a result of B cells not being activated. BCR stimulation, as well as TLR 
4 and 9 stimulation resulted in an increase of HLA-DR expression by B cells (Fig. 3B). 
The expression of CD40, usually responsible for co-stimulation, was also increased. In 
contrast, stimulation using CD40L resulted in a significant up-regulation of IL-15 (Fig. 3A, 
C). Not only did we observe an increased proportion of IL-15/IL-15Rα-expressing B cells, 
but also the ΔMFI (the difference in median fluorescence intensity between isotype and 
sample) of IL-15 and IL-15Rα was significantly higher on CD40L-activated B cells as 
compared to controls (Fig. 3C, pooled data n=4-8 donors). 
1.2 CD40L as a potent stimulus of B cells 
We further examined the up-regulation of Il-15 on the surface of B cells using 
CD40L as an activator of B cells. Co-culturing B cells with CD40L-expressing cells, we 
examined the kinetics of IL-15 up-regulation on the B cell surface to determine the optimal 
time to harvest the cells for subsequent experiments. Experiments looking at B cells after 
2, 3, and 4 days in culture showed that after 4 days in culture, B cells reach a peak in their 
IL-15 expression on the cell surface (Fig. 4A left panel). After 4 days in culture, we also 
see an increased proportion of cells double positive for IL-15 and IL-15Rα (Fig. 4A right 
panel; from 5.7% d2 to 16.0% d4).  
 To confirm the specificity of the stimulus, namely that the up-regulation of IL-15 
was due to interactions with CD40L expressed on the surface of the NIH-3T3 cells, we co-
cultured B cells with either CD40L-expressing or non-expressing (i.e. transfected with an 
empty vector) NIH-3T3 cells. After four days in culture, B cells cultured with the NIH-3T3 
control did not up-regulate the surface expression of IL-15 and IL-15 Rα to any great 
degree as compared to those cultured with NIH-3T3-CD40L cells (Fig. 4B left panel). The  
IL-15
IL
-1
5R
α
3T
3-
C
D
40
L
3T
3-
co
nt
ro
l
isotype B cells
control CD40L
0
5
10
15
20
25
%
 B
 c
el
ls
 IL
-1
5+
 IL
15
R
α
+ ***
0.9 0.1
0.3
1.4 2.4
4.2
1.1 0.2
0.9
8.1 24.1
4.3
B
A
d4     
d3      
d2     
iso
620.4d4 
469.7d3
277.4d2
ΔMFI
IL-15 IL-15
IL
-1
5R
α
13.5
1.4
12.8
1.4
5.7 16.0
d2 d4
Fig.4: Upregulation of IL-15 on B cells via stimulation of CD40 using NIH-3T3 CD40L-
expressing cells. B cells were co-cultured with 3T3-CD40L or control cells in the presence of 
IL-4, and IL-15 and IL-15Rα surface expression assessed by flow cytometry. (A) Histogram 
(left) depicting the kinetics of IL-15 upregulation on B cells as assessed by flow cytometry 
after 2, 3 and 4 days of co-culture with 3T3-CD40L cells. On average, higher levels of IL-15 
expression were seen after 4 days. Dot plots illustrating the typical upregulation of IL-15 and 
IL-15Ra 2 and 4 days after CD40L-activation. (B) B cells cultured with CD40L-expressing 
3T3 cells significantly upregulate IL-15 and IL-15Rα surface expression as compared to B 
cells cultured with control 3T3 cells (no CD40L). Representative FACS plots shown; gated 
on CD20+ B cells. Pooled data shown in right panel (n=6 donors). Statistics: student’s t test,  
* p<0.05, *** p<0.001.
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effect of CD40L stimulation resulted in a very significant increase in the double positive  
population of B cells expressing both IL-15 and IL-15Rα (pooled data from 6 donors, Fig. 
4B right panel). 
As we were adding IL-4 to our 3T3-CD40L-B cell co-cultures, to determine 
whether IL-4 played a role or impacted IL-15 production by B cells, we assessed its 
effects. While IL-4 alone did not affect IL-15 surface expression by B cells, it did have an 
effect on IL-15 production, increasing the impact of CD40L (Fig. 5A). Also, addition of 
IL-4 promoted survival of human B cells in vitro, as fewer cells were positive for a 
LIVE/DEAD staining. 
To confirm that B cells indeed were producing IL-15 and presenting it on the cell 
surface, we carried out a series of experiments. B cells can express IL-15Rα without co-
expression of IL-15. And so, using a sensitive ELISA assay with a detection limit of 
4pg/mL, we examined whether the “empty” receptors would capture and bind soluble IL-
15; upon addition of recombinant IL-15, no surface binding of the cytokine was detected 
after 5 hrs at 370C (data not shown). We also determined that IL-15 is not secreted from B 
cells into the surrounding environment: supernatant from cultures of either untreated or 
CD40L-activated B cells (n=4 donors) was also examined using the ELISA assay, and we 
did not detect any secreted IL-15 (data not shown). We also further confirmed production 
of IL-15 by B cells, comparing the surface and intracellular expression after culture, and 
upon addition of brefeldin A for the last 16h. Untreated cells had virtually no detectable 
IL-15 (Fig. 5B; MFI: isotype: 86; surface: 84; intracellular: 95), but when treated with 
CD40L and IL-4, there was an up-regulation of IL-15 in both the surface and intracellular 
compartments (Fig. 5B right panel; MFI: isotype 293; surface 421; intracellular: 623). 
Lastly, we examined whether the up-regulation of IL-15 was due to a 
corresponding increase in the transcription, as opposed to a recycling of IL-15/IL-15Rα. 
Real-time PCR demonstrated that both IL-15 and IL-15Rα are up-regulated at the mRNA 
level, and that this up-regulation is specific upon stimulation with CD40L (Fig. 5C n= 3 
donors). No IL-15 was detected by qPCR using RNA isolated from 3T3-CD40L cells (data 
not shown). Overall, our results support the notion that B cells synthesized IL-15, which 
was then translocated and expressed on the cell surface, a mechanism similarly seen in 
other cell types.  
Fig 5: Specificity of the upregulation of IL-15 on B cells via stimulation of CD40 using 
NIH-3T3 CD40L-expressing cells. (A) B cells were co-cultured with 3T3-CD40L in the 
absence or presence of IL-4, or with IL-4 or alone for 4 days and then IL-15 and CD40 
surface expression assessed by flow cytometry. (B) Surface and intracellular detection of IL-
15 in B cells as assessed by flow cytometry after 4 days of co-culture with 3T3-CD40L cells 
and IL-4 or no stimulation (nil). Representative FACS plots shown; gated on CD20+ B cells. 
(C) IL-15 and IL-15 Rα are upregulated at the mRNA level relative to 18s rRNA expression. 
B cells activated with CD40L in the presence of IL-4 indicated by B cell-Act. Upregulation is 
specific to stimulation with CD40L-expressing 3T3 cells. Pooled data with n=3 donors. 
Statistics: student’s t test, * p<0.05
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Thus we conclude that IL-15 and its receptor can not only be produced by human B 
cells, but also that their expression can be effectively up-regulated upon CD40L 
stimulation.  
1.3 IL-15 on B cells enhances the cytotoxic profile of CD8 T cells 
To determine the functional effect of the IL-15 produced by activated B cells on 
CD8 T cells, B cells pre-activated via CD40L were incubated with either an IL-15 
blocking Ab or with an isotype control, and subsequently co-cultured with CFSE-labelled 
allogeneic CD8 T cells for 6 days. After 6 days, CD8 T cells were harvested and assessed 
for cell proliferation in addition to granzyme B (GrB) and IFNγ production using flow 
cytometry. One typical example is illustrated and data obtained from 6 CD8 T cell donors 
with 3 donors of B cells are illustrated (Fig. 6). When IL-15 was blocked on B cells, this 
impacted the production of both GrB and IFNγ, resulting in decreased levels being 
produced by CD8 T cells (Fig. 6A and B, left panels, one typical experiment illustrated). 
Overall, the percentage of CD8 T cells that had proliferated and were producing granzyme 
B significantly decreased with the blocking of surface-expressed IL-15 on B cells, and the 
same held true when looking at the total production of granzyme B by CD8 T cells (Fig. 
6A, right panel, n= 6). However, while the same trend was present when examining IFNγ 
production by proliferated CD8 T cells, there was no overall trend in the total IFNγ 
production by CD8 T cells (Fig. 6B, right panels). The increased proliferation of CD8 T 
cells as a result of exposure to surface IL-15 provided by B cells is associated with a 
greater proportion of CD8 T cells displaying a cytotoxic profile, expressing IFNγ and GrB. 
1.4 IL-15 on B cells enhances the ability of CD8 T cells to cross an in vitro BBB 
 Of interest in the pathogenesis of multiple sclerosis, is the infiltration of immune 
cells into the CNS; once in the CNS, immune cells could cause damage to neural tissue. 
However, to reach the CNS, immune cells must first be able to cross the BBB; activated T 
cells display an enhanced capacity to cross the BBB (Engelhardt, 2006). Using a well 
established in vitro model of the BBB consisting of a confluent monolayer of human brain 
endothelial cells (HBECs) (Prat et al., 2000a), we investigated the ability of CD8 T cells to 
cross the barrier in conjunction with the influence of IL-15 expressed by B cells.  
 Pre-activated B cells (using CD40L) were harvested and incubated with a blocking 
antibody to IL-15 or the isotype control, cultured with alloreactive CD8 T cells for 5-6  
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Fig.6: IL-15 presented by B cells is functional and enhances a cytotoxic profile in CD8 
T cells.  B cells pre-activated via CD40L were incubated with either a blocking antibody to 
IL-15 or with an isotype control; B cells were then co-cultured with CFSE-labelled CD8 T 
cells (alloreactive) and proliferation, granzyme B (A), and IFNγ (Β) production by CD8 T 
cells assessed using flow cytometry after 6 days in culture. (A) Left panel: representative 
FACS plots shown. Blocking IL-15 on B cells results in decreased granzyme B production 
and decreased proliferation. Right: Data from multiple donors showing a significant 
decrease in granzyme B production upon blocking IL-15 on B cells. Each pair of dots 
represents an individual donor (n=6 CD8 T cells, n=3 B cells). (B) Left panel: 
Representative FACS plots of IFNγ production by CD8 T cells upon IL-15 exposure. 
Blocking IL-15 on B cells decreases IFNγ production. Summary from multiple donors on 
right (n=6 CD8 T, n=3 B cell donors). There is no overall trend in total IFNγ production by 
CD8 T cells. Statistics: student’s t test, * p<0.05, ** p<0.01.
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Fig.7: IL-15 presented by B cells enhances the ability of CD8 T cells to cross an in 
vitro blood-brain-barrier. (A) B cells were cultured and pre-activated with CD40L, then 
harvested after 3-4 days. B cells were then incubated with either a blocking antibody to IL-
15 or an isotype control, and then cultured with alloreactive CD8 T cells for 5-6 days, after 
which CD8 T cells were harvested and placed on a confluent monolayer of inflamed 
HBECs (an in vitro model of the blood-brain-barrier), and allowed to migrate for 18h. 
Cells in the upper and lower chambers were then counted. (B) Blocking IL-15 on B cells 
before co-culture significantly (* p<0.05, student’s t test) decreases the ability of CD8 T 
cells to cross the inflamed HBEC layer. n=4 CD8 T cell donors
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days. Activated CD8 T cells were harvested and placed in an upper chamber on top of a 
monolayer of inflamed HBECs (Fig. 7A), and allowed to migrate for 18h. Cells from the 
upper and lower chambers were then counted. Blocking IL-15 on B cells before co-culture 
with CD8 T cells significantly decreased the ability of CD8 T cells to subsequently cross 
the in vitro BBB (Fig. 7B, pooled data n=4 donors). B cells are able to upregulate surface 
expression of IL-15 upon stimulation via CD40-CD40L interaction. Furthermore, not only 
do B cells produce and present IL-15 on the cell surface, these enhanced levels are 
sufficient to enhance the cytotoxic profile of CD8 T cells, inducing them to upregulate the 
production of Granzyme B and IFNγ. Lastly, IL-15 presented by B cells to CD8 T cells 
enhances their ability to migrate across an inflamed in vitro model of the BBB. 
2.0 EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS AND IL-15 
2.1 Inducing Experimental Autoimmune Encephalomyelitis: the disease course 
The EAE model, the most commonly used animal model of MS, was established, 
with mice consistently becoming sick, and with similar patterns of disease progression 
between mice of the same background. EAE was induced in SJL/J (SJL) or C57BL/6 (B6) 
mice using either PLP139-151 or MOG35-55 peptides respectively. Disease progression is 
characterized by an ascending paralysis beginning with a limp tail and progressing to hind 
limb then fore-limb paralysis (clinical scoring criteria shown in Fig. 8C). Symptoms 
typically start to show about 7-10 days post-injection. Mice are weighed and scored daily 
according to symptoms; upon 20% weight loss, mice were sacrificed regardless of score. 
In our hands, B6 mice either had acute EAE progressing towards a peak in the 
disease (Fig. 8A left panel), or entered a chronic phase and then went into remission (Fig. 
8A right panel). SJL mice never went into remission, but rather the disease continued to 
progress (Fig. 8B). Furthermore, SJL mice in general had more severe EAE, reaching a 
peak score (< 3.0) sooner than B6 mice. 
2.2 IL-15 expression in EAE: mRNA 
 To determine whether IL-15 expression is up-regulated during EAE, mRNA levels 
in different organs was first assessed. All mice in these and in subsequent experiments 
were perfused with PBS to avoid any contamination from blood cells. 
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Fig.8: Typical clinical scores and disease progression of active EAE induced in 
C57BL/6 and SJL/J mice. Active EAE was induced in both C57BL/6 and SJL mice 
using MOG35-55 or PLP139-151 peptides respectively.  (A) C57BL/6 mice progressed to 
either a peak in disease (score 3.5 – 4.5) or plateau followed by remission to a score of 
0. (B) SJL/J mice progress to a peak in disease (score 3.5 – 5.0). Clinical scoring criteria 
shown in (C). Mice were sacrificed upon reaching a score of 4.5 or at a an end-point 
defined by 20% weight loss. Representative disease course in two individual mice out of 
n=8-10 for acute disease and n=3 for remission of the corresponding genetic background 
are shown for each case.
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2.2.1 IL-15 in spleen and liver 
 IL-15 mRNA was detectable in the spleen and liver of both B6 and SJL mice using 
qPCR (Fig. 9), but levels were significantly greater in B6 mice compared to SJL (scale Fig. 
9). Mice were sacrificed at the onset (score 0.5-1.5) or peak (score < 3.0) of disease, and in 
the case of B6 mice, when in remission (Δscore < 1.0). Control mice were either injected 
with an emulsion containing CFA and PBS or were not injected. B6 mice at onset, peak 
and/or in remission did not show large differences in IL-15 expression relative to 
expression levels seen in control mice in either the spleen or liver (Fig. 9A). In SJL mice, 
at the onset of disease there was slightly less IL-15 at the mRNA level; however at the 
peak of disease, the expression of IL-15 in the spleen and liver was almost 5x lower than 
 those seen in control mice (Fig. 9B). Spleen obtained from very sick SJL animals were 
notably smaller in size compared to controls or mice at onset.  
2.2.2 IL-15 in the CNS 
Distinct areas of the CNS were analyzed by qPCR for IL-15 mRNA levels. CNS 
lesions are more abundant in the spinal cord than in the cortex or brainstem, in the 
conventional EAE induced in SJL mice or B6 (Sobel, 2000). However, lesions in the 
brainstem have been reported under certain circumstances (Lees et al., 2008; Muller et al., 
2000). Also, with time post-disease induction, demyelination progresses from the (lower) 
spinal cord, towards the brainstem and cerebellum (Cross et al., 1993; Sobel, 2000). IL-15 
was expressed in the CNS in both B6 and SJL mice at the mRNA level (Fig. 10). At the 
onset of disease (score 1.5, n=3), there were higher levels of IL-15 mRNA found in the 
brainstem and spinal cord in B6 mice (Fig. 10A) relative to the controls. In the cortex, 
however, at disease onset there was slightly less IL-15 to be found. At the peak of disease 
(score 3.0, n=2), IL-15 mRNA was present and at its highest in the brainstem. Mice in 
remission (score 0, n=3) have almost no IL-15 in the brainstem, but it is detectable in the 
spinal cord, as well as in the cortex. While the highest levels of IL-15 were to be found in 
the brainstem at the onset and peak of disease, and the lowest levels found at remission 
again in the brainstem, the greatest change in IL-15 expression with disease progression 
occurred in the spinal cord at onset and the peak of disease (Fig. 10A, fold increase of 3.4 
and 3.7 at onset and peak respectively in the spinal cord, compared to 1.8 and 2.1 in the 
brainstem). 
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Fig.9: Quantification of IL-15 mRNA levels in spleen and liver of B6 and SJL mice 
using qPCR. Spleen and liver were harvested from PBS-perfused mice, RNA extracted, 
transcribed into cDNA and qPCR performed as described in methods. Results are 
presented as relative expression compared to the endogenous Hprt1 gene. Number above 
column indicates expression level compared to control group. (A) Organs harvested 
from B6 mice. Small differences or changes in expression level of IL-15 as compared to 
controls or at different points of disease (onset, peak or remission). (B) Organs from SJL 
mice. Expression level of IL-15 is decreased during disease relative to controls (n= 2-3 
for each group) ctl, control; onset, score 0.5-1.5; peak, score 3.0-4.5; rem, remission Δ
score >1.0. 
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Fig.10: Expression of IL-15 in various parts of the CNS in B6 and SJL mice. Cortex, 
brainstem and spinal cord were harvested from PBS-perfused mice, RNA extracted, 
transcribed into cDNA and qPCR performed as described in methods. Results are 
presented as relative expression compared to the endogenous Hprt1 gene. Number above 
column indicates expression level compared to control group. (A) Organs harvested 
from B6 mice (B) Organs harvested from SJL/J mice. n=2-3 mice for each stage of 
disease.
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Overall and in general, there were relatively higher levels of IL-15 detected in B6 mice as 
compared to SJL mice. In the cortex, there was no change in IL-15 expression at the onset 
of disease; however at the peak of disease, IL-15 mRNA levels decreased in SJL/J mice. 
There was no substantial change in IL-15 expression in the brainstem during the course of 
disease. In the spinal cord, while changes were not as large as those seen in the B6 mice 
during disease, there was an increase in the IL-15 mRNA levels at both onset and peak of 
disease (Fig. 10B).  
 Thus, IL-15 mRNA levels were up-regulated in the spinal cord, the main site of 
CNS lesions, of both strains at onset and peak of disease. 
2.3 IL-15 in EAE: infiltrating immune cells express IL-15 and IL-15Rα 
As the surface-bound form of IL-15 is mainly responsible for cellular signaling to 
neighboring cells (Budagian et al., 2006), surface expression of IL-15 and IL-15Rα on ex 
vivo immune cells was assessed by flow cytometry. In order to be certain that what we 
were seeing were cells positive or negative for IL-15 and/or the receptor alpha chain, we 
chose fluorochromes for each of these two molecules so as to not have potential influence 
due to compensation problems. And so, for the following experiments, IL-15 was labelled 
with an anti-IL-15 PE-labelled antibody, and IL-15Rα was first labelled with a biotinylated 
antibody followed by streptavidin conjugated to APC. Leukocytes were isolated from the 
spleens, draining lymph nodes (DLN) (to the emulsion injection site) and the CNS of both 
B6 and SJL mice at onset and peak of disease.  
As the qPCR results indicated that IL-15 was expressed during EAE disease 
progression in the CNS, we examined the profile of immune cells present in each of the 
harvested organs using flow cytometry, with regards to IL-15 expression. Gating on CD3 
negative cells, preliminary results showed the presence of IL-15 and IL-15Rα-expressing 
immune cells in the CNS of B6 mice and SJL mice at the onset (Figs. 11 and 12 
respectively, panel A; representative of 2-3 mice) and peak of disease (Figs. 11 and 12, 
panel B, representative of 4 mice). This expression of IL-15 and IL-15Rα on non-T cells 
seemed to be specifically localized to immune cells present in the CNS, although slightly 
more cells expressing IL-15Rα were present in the DLN and the spleen in B6 mice at the 
onset of disease compared to mice at the peak of disease (Fig. 11A dot plots for DLN and 
SPLN vs. Fig. 11B DLN and SPLN). Also at the onset of disease, IL-15+/IL-15Rα- cells 
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Fig.11: Immune cells found in the CNS of B6 mice express both IL-15 and its 
receptor alpha-chain. B6 mice were sacrificed (perfused with PBS) at either the onset 
or peak of disease. Leukocytes were isolated from various organs (spleen (SPLN); 
draining lymph nodes (DLN); or CNS) and subsequently stained and analyzed by flow 
cytometry. Plots are gated on CD3 negative cells (CD3-). IL-15 and IL-15Rα-
expressing cells were specifically found in the CNS, and were not present in the DLN or 
SPLN of the same animal. Representative FACS plots for mice at onset (n=3) or peak 
(n=4) of disease. B6 mouse at (A) onset (score 1.5) and (B) peak of disease (score 4.5).
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Fig.12. IL-15 and IL-15Rα-expressing cells are specifically found in the CNS of SJL 
mice, and are not present in the DLN or SPLN. SJL mice were sacrificed (perfused
with PBS) at either the onset or peak of disease, leukocytes isolated from various organs 
(spleen (SPLN); draining lymph nodes (DLN); or CNS) and subsequently stained and 
analyzed by flow cytometry. Plots are gated on CD3 negative cells (CD3-). 
Representative FACS plots for mice at onset (n=2) or peak (n=4) of disease. SJL mouse 
at (A) onset (score 1.0) and (B) peak of disease (score 4.5).
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were detected in lymphoid organs of both strains, but not at the peak of disease. This was 
not seen in the SJL mice (Fig. 12A and B). It was not possible to analyze CNS cells from 
control animals as very few cells could be recovered from these mice.  
2.4 CNS-infiltrating immune cells expressing IL-15  
 We further characterized the immune cells present in the CNS of SJL and B6 mice, 
expressing IL-15 and IL-15Rα using flow cytometry. As a preliminary screening, we 
chose the markers CD11b (indicative of a macrophage/microglial population) and B220, a 
marker found predominantly on B cells. Again to avoid problems with compensations, Ab-
fluorochrome combinations were carefully chosen: CD11b was labeled with Alexa 700 and 
B220 with Alexa 488. Upon examination of the CNS-infiltrating cells in B6 mice, the 
proportion of CD3- cells expressing IL-15 also expressed IL-15Rα (20.5%; Fig. 13A); a 
proportion of these cells were CD11b+ (13.2%; Fig. 13A ii), but the majority were double 
positive for CD11b and B220 (86.8%). A proportion of cells expressing only the IL-15Rα 
(67.2% CD3- cells; Fig. 13A), when further characterized, also showed a CD11b+ and 
CD11b+/B220+ profile (Fig. 13A i). When compared to the peak of disease, the proportion 
of CD3- cells IL-15+/IL-15Rα+ found in the CNS of B6 mice were CD11b+ and B220- 
(Fig. 13B ii). There was also a small subset of immune cells expressing IL-15, but negative 
for the receptor; these too were CD11b+ (Fig. 13B iii).  
 In contrast to the results seen in B6 mice, the profile of the immune cells found in 
the CNS of SJL mice at the same points of disease is different. At the onset of disease, 
cells positive for IL-15Rα are CD11b+ (Fig. 14A i). The proportion of double positive 
cells for IL-15 and the Rα, unlike those in the CNS of B6 mice, are positive for only 
CD11b (Fig. 14A ii). Cells positive for only IL-15 are either CD11b+ or B220+, with the 
majority being CD11b+ (54.7% compared to 26.2%; Fig. 14A iii). A similar profile exists 
for the CNS immune cells at the peak of disease (Fig. 14B i, ii, iii). The B220+ CD11b- 
population expressing IL-15 was not observed in B6 mice.  
 This characterization of immune cells present in the CNS of mice with active EAE 
at either onset or peak of disease indicated that further analysis of IL-15-expressing cell 
populations using additional markers will more precisely identify the immune cells 
expressing IL-15 in the CNS. For instance, immune cells double positive for CD11b and 
B220 have been previously described (Davoust et al., 2006) in the context of chronic EAE; 
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Fig.13. Characterization of IL-15-expressing lymphocytes isolated from CNS 
of B6 mice. Leukocytes were isolated from the CNS of PBS-perfused B6 mice 
with EAE, using a Percoll gradient. Cells were then stained and analyzed by flow 
cytometry (A) B6 mice at onset of disease (score 1.5). Proportion of cells co-
expressing IL-15 and IL-15Rα are CD11b+ and B220-. (B) B6 mice at peak of 
disease (score 4.0). Cells positive for IL-15 are also CD11b+. Top panels of (A) 
and (B) gated on CD3 negative (CD3-) cells. Representative FACS plots of n=3-4 
mice for each stage of disease.
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Fig.14. Characterization of IL-15-expressing lymphocytes isolated from the CNS of 
SJL mice. Leukocytes were isolated from the CNS of PBS-perfused SJL mice using 
Percoll gradient. Cells were then stained and analyzed by flow cytometry (A) SJL mice 
at onset of disease (score 1.0). IL-15+IL-15Rα+ cells are CD11b+B220-. IL-15+ cells 
are either CD11b+B220- or CD11b-B220+. (B) SJL mice at peak of disease (score 4.0). 
Double positive cells are also CD11b+. Cells positive for only IL-15 are CD11b-B220+ 
or CD11b+B220-. Top panels of (A) and (B) gated on CD3 negative cells. 
Representative FACS plots of n=2-4 mice for each disease stage.
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 their data suggest that these CD11b+/B220+ cells (also CD34+ in their study) develop into 
a subpopulation of microglial cells under neuroinflammatory conditions. However, we can 
still conclude that although further characterization of these immune cells is required, 
immune cells were present in the CNS of B6 and SJL mice expressing IL-15. Furthermore, 
IL-15 expression was specific to the immune cells found in the CNS and was not seen in 
those found in the spleen or in the draining lymph nodes. Results are representative of 2-4 
mice; percentages varied between mice, but the overall trend remained the same. 
2.5 T cells found in the CNS of mice with active EAE are responsive to IL-15 
 Signaling occurs through the IL-15Rβ (CD122) chain, shared with IL-2, and 
common γ chain, shared with other interleukins. IL-15Rα is required to bind strongly to 
IL-15 and to present the cytokine to the other receptor components. To determine whether 
T cells present in the target organ of EAE could respond to these increased levels of IL-15, 
leukocytes isolated from spleen, draining lymph nodes and the CNS of B6 and SJL mice at 
the onset and peak of disease were assessed for IL-15 receptor expression using flow 
cytometry (Figs. 15 and 16; representative of 2-4 mice). Overall, a greater proportion of T 
cells found in the CNS expressed both the alpha and beta chains (IL-15Rα and CD122 
respectively) of the IL-15 receptor than did T cells found in the draining lymph nodes and 
spleen of the same animals. However, an important proportion of the T cells in the DLN 
and spleen did express the beta chain, which is shared with IL-2.  
 At the onset and peak of disease, a higher proportion of CD8 T cells found in the 
CNS of B6 mice expressed the alpha chain as compared to CD4 T cells (Fig. 15A and B, 
CNS panels).  At onset, in the DLN and spleen, a proportion of T cells were double 
positive for both IL-15Rα and CD122; again greater in the CD8 T cell population than in 
the CD4 population (Fig. 15A). However, this diminished at the peak of disease, where we 
no longer saw the IL-15Rα positive cells present in either the DLN or spleen (Fig. 15B). In 
the CNS of SJL mice, we saw the same trend in the CNS, with a greater proportion of CD8 
T cells expressing IL-15Rα and CD122 than CD4 T cells (Fig. 16A, B). However, the 
difference between onset and peak of disease with regards to the expression of IL-15Rα 
was not as pronounced in the DLN and spleen of SJL mice (Fig.
16A, B, DLN and SPLN panels). Overall, this indicates T cells found in the CNS were 
potentially responsive to IL-15. 
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Fig.15. T cells found in the CNS of B6 mice are potentially responsive to IL-15. 
Leukocytes were isolated from organs obtained from PBS-perfused mice. Cells were then 
stained and analyzed by flow cytometry A greater proportion of CD8 T cells express 
CD122 in the CNS compared to T cells found in the draining lymph nodes (DLN) or in the 
spleen (SPLN). Representative FACS plots for mice at onset (n=3) or peak (n=4) of 
disease. B6 mouse at (A) onset, score 1.5 or (B) peak of disease, score 4.5. 
isotype
CD122
IL
-1
5R
α
59.2
10.4
3.5
16.8
5.8
1.1
34.2
48.4
58.3
56.8
28.8
30.0
0.6
1.0
2.0
CD8+ CD4+
C
N
S
D
LN
SP
LN
A B
85
CD8+ CD4+
CD122
IL
-1
5R
α
isotype
36.1
4.3
2.1
7.1
0.3
0.6
23.6
32.2
19.5
30.9
39.6
13.4
0.9
1.1
3.0
C
N
S
D
LN
SP
LN
CD122
IL
-1
5R
α
C
N
S
D
LN
SP
LN
isotype
CD8+ CD4+
0.9
1.1
3.0
14.6
70.7
5.7
63.5
0.6
23.2
2.0
47.2
0.6
21.3
0.3
10.8
A B
Fig.16: T cells found in the CNS of SJL mice are potentially responsive to IL-15. 
Leukocytes were isolated from organs obtained from PBS-perfused mice. Cells were then 
stained and analyzed by flow cytometry A greater proportion of CD8 T cells express 
CD122 in the CNS compared to T cells found in the draining lymph nodes (DLN) or in the 
spleen (SPLN). Representative FACS plots for mice at onset (n=2) or peak (n=4) of 
disease. SJL mouse at (A) onset, score 1.5 or (B) peak of disease, score 4.5.
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 IL-15 is a pleiotropic cytokine expressed in various tissues and cells at the mRNA 
level. However, at the protein level, IL-15 is not as extensively expressed; translation is 
under several regulatory checkpoints (Fehniger and Caligiuri, 2001). IL-15 is important for 
the development, homeostasis and activity of NK cells, as well for the survival and 
expansion of CD8 T cells. In conjunction with IL-7, IL-15 plays a crucial role in the MHC-
independent homeostasis of memory CD8 T cells (Surh and Sprent, 2008). It is the role 
this cytokine plays in the maintenance of CD8 T cells that makes it a candidate for aberrant 
activation of T cells. CD8 T cells are already implicated in various diseases, due to their 
ability to directly target and kill cells. Under normal conditions, such an immune response 
is useful and necessary in the clearance of intracellular pathogens, but when disregulated, 
can lead to autoimmune disorders. IL-15 is a cytokine implicated in the maintenance and 
triggering of autoreactive CD8 T cells (Ramanathan et al., 2011) and also plays a crucial 
role in CD8 T cell migration and survival in organs (McGill et al., 2010; Verbist et al., 
2011). Furthermore, it has already been implicated in various autoimmune diseases. In the 
context of MS, elevated levels of IL-15 and IL-15Rα, required for trans-presentation of 
this cytokine to effector cells, are found in the CNS at the mRNA level (Kurowska et al., 
2002), surface-expression of IL-15 on monocytes has been reported in MS patients 
(Vaknin-Dembinsky et al., 2008), and our lab has shown elevated levels of IL-15 
expressed by astrocytes and microglia/macrophages in MS lesions (Saikali et al., 2010). 
 
1.0 EXPRESSION OF IL-15 BY HUMAN B CELLS 
We have shown that with specific stimulation, B cells up-regulate the expression of 
both IL-15 and IL-15Rα, and present it on the cell surface. Furthermore, the IL-15 levels 
presented by activated B cells are sufficient to induce activation of CD8 T cells, enhancing 
the production of both granzyme B and IFNγ. Not only does IL-15 presented on B cells 
promote a cytotoxic profile of CD8 T cells, but also the ability of CD8 T cells to migrate 
across an in vitro BBB is significantly enhanced upon exposure to IL-15-expressing B 
cells. 
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1.1 Up-regulation of IL-15 expression 
From among the various stimuli including HMGB1, CpG, LPS and αhu Ig, we 
tested, only one, CD40L, was sufficient to significantly enhance expression of IL-15 by B 
cells (Fig. 3A and C; Fig. 5C). The stability of surface IL-15 on B cells is unknown; 
however IL-15 has been described to be recycled through endosomal vesicles of 
monocytes and DCs, allowing for the persistence of membrane-bound IL-15 for many days 
(reviewed in (Waldmann, 2006)). The expression of IL-15 on B cells may perhaps be 
maintained via the same mechanism; furthermore it would be of interest to investigate 
whether the stimulation of B cells triggers a transport of intracellular pools of IL-15 to the 
cell surface in response.  
In the context of disease, CD40L as a stimulus is highly relevant: MS patients have 
a higher frequency of CD40L-expressing T cells than controls (Teleshova et al., 2000), and 
activated CD4 T cells expressing CD40L are found in MS patient brains (Gerritse et al., 
1996b). In addition, CD40-expressing cells are also found in MS patient brain tissue, most 
of which are either CD11b+ macrophages/microglia or B cells (Gerritse et al., 1996b). 
Astrocytes have also been found to express CD40 (Kim et al., 2011). Other stimuli tested 
(HMGB1, CpG, LPS, αhu Ig) did not result in up-regulation of IL-15, although HLA-DR 
expression was enhanced (Fig 1B), indicating the cells were activated. While activation via 
TLR stimulation did not induce a significant up-regulation of IL-15 (Fig. 3A and C), using 
such stimuli still warrants further investigation. Levels of TLR expressed by B cells vary 
according to the subset under consideration (Booth et al., 2011), and thus the varied or lack 
of response to TLR agonists may differ according to the proportions of cell subsets and to 
TLR levels.  
Although we did not look at specific B cell subsets, it would be interesting to 
examine the response of these subsets to TLR stimulation. For instance, while TLR4 and 
TLR1 mRNA is detected in all B cell subpopulations, TLR7 and TLR9 levels vary 
depending on the B cell subset (Bekeredjian-Ding and Jego, 2009); TLR9 while not on 
naïve B cells, is expressed by memory B cells (Gururajan et al., 2007). TLR3 mRNA is 
detected only in marginal zone B cells, but TLR2 is most prominent in B-1 B cells 
(Bekeredjian-Ding and Jego, 2009). Thus the response to TLR stimulation would most 
likely vary, depending on the activation state and the subset of B cell present in culture. 
Further investigation into the response to TLR stimulation by B cells is warranted, using 
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such markers as IgD and CD27 to differentiate between naïve and memory B cells (IgD is 
down-regulated in B cells acquiring the memory marker CD27) (Bleesing and Fleisher, 
2001); CD23 and CD21 can be used to identify marginal zone B cells (CD23-CD21+) from 
follicular B cells (CD23+CD21-) (Gururajan et al., 2007). 
Several lines of evidence indicate a role for TLRs in the pathogenesis of MS, and in 
EAE, and considering the effects of TLR stimulation on B cells including up-regulation of 
cytokine secretion, there might very well be a role for TLR stimulation in the production of 
IL-15 under specific conditions. For instance, TLR9 is constitutively expressed by B cells 
and DC (Marshak-Rothstein and Rifkin, 2007). Stimulation of TLR9 results in 
exacerbation of disease in an animal model of MS (Brien and Gran, 2008) and conversely, 
the absence of TLR9 (i.e. TLR9 -/- mice) results in a delayed EAE induction and decreased 
disease severity (Prinz et al., 2006); furthermore, a decrease in the expression of TLR4 
and/or 9 has been associated with amelioration of EAE (Chearwae and Bright, 2008). 
While normally TLR9 recognizes viral and bacterial DNA, it has also been shown to 
recognize host genetic material (Marshak-Rothstein and Rifkin, 2007), which may very 
well be found in active MS lesions with ongoing cell damage. However stimulation 
through TLR9 alone may be insufficient to induce up-regulation of cytokines, and 
additional stimuli through other TLRs or other means may be required.  
TLRs can regulate the expression of other TLRs, as in the case with TLR 2 and 9 
regulating TLR4 expression on B cells (Jagannathan et al., 2009). In the case of TLR4, B 
cells typically express very low levels, but upon activation or under inflammatory 
conditions, they are capable of up-regulating expression of TLR4 (Jagannathan et al., 
2009; Mita et al., 2002). Here, we used LPS from E. coli as a stimulus; however 
considering the normally low expression levels of TLR4, it may indicate pre-activation or 
simultaneous stimulation of B cells is required to induce a response in spite of the typically 
potent effects of LPS in the immune response. Alternatively, perhaps stimulation using 
such agonists as would be found in MS lesions would be more relevant, as they may have 
additional (inflammatory) effects via pathways other than TLR stimulation. While 
typically TLR ligands have been described to be PAMPs, non-pathogenic molecules have 
also been described to trigger inflammation: host genetic material via TLR9 (Marshak-
Rothstein and Rifkin, 2007), and agonists of TLR2 and TLR4 include heat shock proteins 
(Hsp), proteolytic cleavage products and extracellular matrix components (Kigerl et al., 
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2007). One such possible stimulus could be Hsp70, which has been found in MS lesions 
and associated with MBP and PLP, the two most abundant proteins of the CNS myelin 
sheath (Aquino et al., 1997; Cwiklinska et al., 2003). Over-expression of Hsp70 in vitro 
enhances the activation of APCs, and induces immune cells to produce cytokines and 
chemokines (Turturici et al., 2011); an enhanced production of IL-15 could be possible 
using this stimulation. Of course, it is also quite possible that the stimulation of TLRs on B 
cells has no direct effect of the production of IL-15, but rather simply serves to enhance or 
support the activation state of B cells, and prolong cell survival. 
Thus, while stimulation of various TLRs did not induce an up-regulation of surface 
IL-15, this could be due to B cells expressing low basal levels of the TLR, as in the case of 
TLR4, the need to use a more disease-relevant stimulus, or the requirement for additional 
stimulus, either through another TLR or other means such as BCR cross-linking. Multiple 
stimuli, or combinations of stimuli might also be required to have an effect; for instance, in 
inducing an up-regulation of IL-15 on astrocytes, a combination of cytokines was required 
rather than any one stimulus alone (Saikali et al., 2010).  CD40L, in contrast to TLR 
stimulation, proved to be a sufficient stimulus for B cells in significantly up-regulating the 
expression of IL-15, and IL-15Rα, by B cells at the mRNA and protein levels. 
Contributing to the different effects of the various B cell stimuli, CD40 signals through a 
different pathway, stimulation recruiting various TNFR associated factors (Peters et al., 
2009b) as opposed to activation of the MyD88 pathway, providing an explanation as to the 
differing effects of CD40 vs. TLR stimulation of B cells in promoting IL-15 expression. 
1.2 Effect of IL-15 on CD8 T cells 
We examined the functional effects of IL-15-expressing B cells on CD8 T cells, 
and found that the cytotoxic profile was enhanced. Exposure to surface IL-15 expressed by 
B cells increased proliferation and the expression of granzyme B (Fig. 6A) and IFNγ (Fig. 
6B). However, there was no overall trend in the effect of IL-15 on total IFNγ production 
whereas there was a significant production of granzyme B by proliferated and total CD8 T 
cells, in response to IL-15. A previous study has shown IL-15 to be more important in the 
up-regulation of granzyme B than for that of IFNγ by CD8 T cells (Marshall et al., 2010).   
Furthermore, the ability of CD8 T cells to migrate across an in vitro BBB was affected by 
the presence or absence of IL-15. Blocking IL-15 on B cells led to a significant decrease in 
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the number of CD8 T cells which migrated across the BBB (Fig. 7B). We confirmed that 
the increased migration of CD8 T cells in the presence of IL-15 was not due to a breach in 
the integrity of the in vitro BBB (data not shown). Interestingly, a study done by Suidan et 
al. demonstrates a non-apoptotic perforin dependent mechanism for CD8 T cells to disrupt 
the tight junctions of the BBB and migrate into the CNS, in a viral model of MS (Suidan et 
al., 2008). Since it seems CD8 T cells activated by IL-15 migrated across our model of the 
BBB without damaging the cells, it would be interesting to examine the role of perforin in 
our model of BBB trans-migration, and the role IL-15 plays, if any, in influencing its 
expression levels by CD8 T cells. It would also be interesting to look at the possible up-
/down-regulation of various other molecules found on activated CD8 T cells, such as PD-1 
and Fas. 
The effect IL-15 presented by B cells has on the cytotoxicity and migration ability 
of CD8 T cells is of interest, considering the effects of B cell depletion in multiple 
sclerosis. B cell depletion with rituximab, a CD20 monoclonal Ab, has been effective in 
that the occurrence of relapses and new gadolinium-enhancing lesions in MS patients are 
reduced (Hauser et al., 2008). The effects of this treatment are not due to depletion of Ab-
producing plasma cells and only a modest reduction of anti-myelin antibodies has been 
reported (Cross et al., 2006); the long-term effect of this treatment on antibody levels are 
as yet unknown. As it seems B cell depletion in MS patients does not have an effect via Ab 
depletion, there must be an alternative mechanism. It is likely that removing B cells from 
the peripheral blood interferes with the activation of T cells mediated by pro-inflammatory 
cytokines and co-stimulatory molecules such as CD86 provided by B cells (Bar-Or et al., 
2010). Interestingly, we also observed elevated levels of CD86 expressed on B cells after 
stimulation with CD40L; thus IL-15 could be one such cytokine influencing the activation 
state of T cells and their cytotoxic response in MS.  
Considering the involvement of IL-15 in MS and other inflammatory diseases, the 
question must be asked whether there are any polymorphisms in either the cytokine or 
receptor genes which are associated with disease. Polymorphisms in IL-15 have been 
shown in specific populations of patients with psoriasis (Weger et al., 2008; Zhang et al., 
2007), and have been indicated in an increased risk for coronary heart disease (Gokkusu et 
al., 2010). However, in rheumatoid arthritis, a screen of IL-15 polymorphisms did not 
demonstrate a role for IL-15 gene polymorphisms in genetic predisposition to developing 
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rheumatoid arthritis. Overall, there does not seem to be a strong relationship between 
variants of IL-15 or IL-15Rα and any one disease; further studies perhaps need to be 
carried out. 
In conclusion, IL-15 is up-regulated on B cells under inflammatory-like conditions, 
and is capable of promoting proliferation in addition to enhancing the cytotoxic profile and 
trans-migration capacity of CD8 T cells. Elevated IL-15 levels have been implicated in 
various inflammatory diseases, and interestingly CD8 T cells have also been implicated in 
many of them as well (Liu et al., 2000; Mention et al., 2003; Ramanathan et al., 2011; 
Sakai et al., 1998). Clinical trials targeting IL-15 in various inflammatory diseases have 
been completed or are ongoing. These potential therapies block IL-15 using soluble anti-
IL-15 antibodies. Therapeutic strategies specifically targeting this cytokine could equally 
be beneficial in ameliorating the course and severity of MS, by decreasing CD8 T cell 
cytotoxicity as well as by limiting access to the inflamed CNS thus diminishing CD8 T 
cell-mediated damage. On the other hand, boosting the levels and effects of IL-15 on CD8 
T cells would be beneficial, in such cases as cancer, where a cytotoxic response is wanted.  
 
2.0 CHARACTERIZATION OF IL-15 IN CLASSICAL EAE 
EAE is a much used animal model for Multiple Sclerosis. While it is not able to 
fully mimic the disease as it is found in humans, various aspects of the disease can be 
studied and the influences and roles of various factors examined so as to extrapolate 
potential culprits of disease pathogenesis back to the human disease. There are studies 
examining the role of IL-15 in EAE (Gomez-Nicola et al., 2010; Wu et al., 2010) as well 
as in other neuroinflammatory models (Gómez-Nicola et al., 2008b). However the 
expression pattern of IL-15 during the course of disease has not been characterized. 
Characterizing the expression of IL-15: when it is expressed, where it is expressed, to what 
degree is expression up- or down-regulated, is relevant to understanding the effects and 
role of IL-15 in disease exacerbation, or amelioration. 
We compared the course of active EAE induced in two different strains of mice: 
SJL/J and C57BL/6, and examined the IL-15 expression in each at various stages of 
disease. All mice chosen for this study had similar disease courses. However, it would be 
interesting in future studies to expand the study to include mice with atypical EAE, as well 
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as mice which had a more rapid disease progression to be able to examine the potential 
variation that exists not only between genetic backgrounds, but also if there are differences 
in IL-15 expression related to the severity and course of disease. We were able to detect 
IL-15 at both the mRNA and protein level in the CNS of these mice during the course of 
disease. The presence of IL-15 was specific to the CNS, and was not found in either the 
spleen or draining lymph nodes. 
2.1 Detection of IL-15  
In general, it is difficult to detect IL-15 in mice, thus we elected to first look for IL-
15 expression using qPCR, and to see if there were any differences in the expression levels 
in various components of the CNS of this cytokine during the course of disease in mice 
with EAE. 
We detected IL-15 at the mRNA level in both SJL and B6 mice, at the onset and 
peak (and remission) of disease. In B6 mice, there were no significant differences in IL-15 
expression levels detected in the spleen and liver of these animals during disease as 
compared to control mice (Fig. 9A). However, upon examining component parts of the 
CNS, we saw differences in IL-15 expression during the course of disease, with IL-15 
levels in the cortex lower than that of controls during the course of disease; in the 
brainstem, at the onset and peak there was increased IL-15 expression but in remission 
almost no IL-15 was detected; and in the spinal cord, IL-15 was more expressed during the 
course of disease (Fig. 10A). In SJL mice, we did not detect differences in IL-15 
expression in the CNS to the extent observed in B6 mice (compare Fig 10B with 10A), 
with the exception of the decrease in IL-15 expression at the peak of disease in the cortex. 
However, it seems that IL-15 may be down-regulated during the course of disease in 
general, but not in the CNS: in the spleen and liver of SJL mice at the peak of disease, 
there was decreased IL-15 expression as compared to controls (Fig. 9B). It must be noted 
that EAE induced in SJL mice is primarily a CD4 T cell-mediated disease. While IL-15 
has been demonstrated to have an effect on CD4 T cells (Vaknin-Dembinsky et al., 2008), 
but its effects have primarily been described on CD8 T cells. Thus perhaps the levels of IL-
15 in SJL mice are reflective of the extent to which CD8 T cells play a role in disease 
pathogenesis in this particular model. 
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The detection of IL-15 mRNA and the differences in expression level found in 
various components of the CNS indicated there might be differences in the expression of 
IL-15 at the protein level during the course of disease, even though the presence of mRNA 
does not always necessarily correspond to translated protein and thus protein levels. 
However, we were able to detect IL-15 expressed on the surface of immune cells isolated 
from the CNS (brain and spinal cord) of PBS-perfused animals. 
The expression of IL-15 protein was limited specifically to the CNS, and was not 
detected in the spleen or in the draining lymph nodes to the emulsion site. Furthermore, we 
also examined the expression profile of the IL-15Rα chain, and found that it was also 
expressed specifically in the CD3 negative cells found in the CNS. However, a small 
proportion (10-12%; Fig. 11A) of CD3 negative cells in the spleen and draining lymph 
node at the onset of disease expressed IL-15Rα. This was specific to B6 mice only. In SJL 
mice at the onset of disease, a proportion of CD3 negative cells in the draining lymph node 
and, to a lesser extent, in the spleen, expressed IL-15, without co-expression of the Rα.  
Interestingly, using CD11b and B220 as markers for macrophages/microglia and B 
cells respectively, we found differences in the cell profiles of IL-15-expressing immune 
cells in the CNS of B6 and SJL mice. In B6 mice, we observed a population of 
CD11b+B220+ cells present in the CNS at the onset of disease, which was not seen in the 
SJL mice (Fig. 13A). Normally CD11b is a marker for macrophages/microglia and B220 
for B cells. However, a previous study has described a population of CD11b+B220+ (and 
CD34+) cells found in the murine brain under neuroinflammatory conditions (Davoust et 
al., 2006). Their study suggests that a pool of CD34+CD11b+B220+ cells migrating from 
the periphery into the CNS may proliferate and give rise to activated microglia, double 
positive for CD11b and B220, and thus promote ongoing CNS inflammation. Interestingly, 
they also define a population of cells which are CD34+B220+ but CD11b-, suggesting that 
they may be microglial progenitors, based on a study identifying CD11b- myeloid 
progenitors in the CNS (Alliot et al., 1991; Davoust et al., 2006). In our study, we did not 
see a population of CD11b-B220+ cells in the CNS of B6 mice. However, such a 
population was identified in the CNS of SJL mice. Whether these cells have the capacity to 
proliferate and differentiate into microglial cells would be interesting to determine. Further 
characterization of the immune cells found in the CNS at both peak and onset of disease is 
necessary. In addition, it would be interesting to compare the cell profile of immune cells 
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found in the CNS of mice in remission during the course of EAE, as well as those of IL-
15+IL-15Rα+ vs. IL-15+IL-15Rα- cells. B220, while commonly used as a pan-marker for B 
cells, is also expressed on activated NK and T cells, as well as on NK progenitors (Lai et 
al., 1998), and so other markers may be used to identify more precisely the IL-15+IL-
15Rα- expressing cells in the SJL CNS. These could include CD19, a marker more 
restricted to the B cell lineage, CD80 and CD86 in conjunction with CD19 would identify 
activated B cells, CD23, CD5 and CD11b expression can be used to distinguish between 
“conventional” and “non-conventional” B cells (Lai et al., 1998).  
In the B6 mice, the profile of cells expressing IL-15 and/or IL-15Rα had similar 
profiles. At onset, there was a population of cells double positive for CD11b and B220, as 
well as a population expressing only CD11b. At the peak of disease, cells were found to be 
mainly CD11b positive. However, cells expressing only IL-15 without detection of the IL-
15Rα, while expressing CD11b, seemed to express it at lower levels as compared to cells 
expressing IL-15 and/or IL15Rα. In SJL mice, the profiles of IL-15-expressing immune 
cells were considerably different from those seen in B6 mice. First, the cell population 
positive for only IL-15Rα were mostly positive for CD11b. Interestingly, there seems to be 
two populations: one that expresses high levels of CD11b, and another still expressing 
CD11b but lower levels. The IL-15/IL-15Rα double positive population of CD3 negative 
cells was CD11b+. Lastly, the cells expressing IL-15 but not IL-15Rα were either CD11b+ 
(approximately 55%) or B220+ (26-33%). The differences in the profile of cells found in 
the CNS of B6 and SJL mice indicate that there are differences in IL-15 expression due to 
genetic background and course of disease. SJL mice often showed symptoms sooner than 
B6 mice and followed a more severe course of disease, reaching our defined end-points 
sooner than their B6 counterparts. The presence of immune cells presenting IL-15 in the 
CNS as well as the differences noted, seem to indicate that perhaps IL-15 does have a role 
in the course of EAE, either in promoting inflammation or influencing the course and 
severity of disease. Further work needs to be done, to quantify the number of cells 
expressing IL-15. 
There are various reports of the role of IL-15 in neuroinflammation. On the one 
hand, IL-15 has been reported to have beneficial effects in EAE (Wu et al., 2010), and that 
IL-15 knockout mice have more severe EAE (Gomez-Nicola et al., 2010). However, mice 
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deficient in IL-15 have an impaired immune system to begin with, with low numbers of 
NK and memory CD8 T cells (Kennedy et al., 2000), and the average clinical score of the 
wild-type mice in these studies (Gomez-Nicola et al., 2010; Wu et al., 2010) are quite low 
(average score of 1.0-1.5), as compared to other reports and to what we obtained in our 
study. This would indicate that conclusions drawn from these studies using IL-15 knockout 
mice must be made with caution. Indeed, on the other hand there are reports of IL-15 
playing a role in aggravating neuroinflammation and that inhibiting its effects would be 
beneficial. One study found that the expression of IL-15 served as a signal for macrophage 
and T cell activation and infiltration into the CNS (Gómez-Nicola et al., 2008b). Blocking 
the activity of IL-15 in the CNS under inflammatory conditions prevented glial activation 
and reduced the production of pro-inflammatory molecules such as IL-1β. Thus the 
potential role of IL-15 in neuroinflammation, more specifically in EAE, is still uncertain, 
and requires further investigation. 
 Further adding to the complexity, CD122+ CD8 T cells have been reported to have 
a regulatory role in EAE (Lee et al., 2008). Depletion of these cells resulted in persistent 
disease and increased infiltration and cytokine production of T cells in the CNS. Transfer 
of CD122+ CD8 T cells at the peak of EAE resulted in diminished EAE symptoms, 
especially in the recovery phase of disease (Lee et al., 2008). Studies have shown these 
cells to be involved in the regulation of CD122- CD8 T cells independent of Ag (Rifa'i et 
al., 2004) and suppress proliferation of CD122- cells by secreting IL-10 (Endharti et al., 
2005). These regulatory CD8 T cells are potentially responsive to IL-15; however they are 
also responsive to IL-2. The relative contribution of each of these cytokines may be one of 
the determining factors for the development of a regulatory response by CD8 T cells. 
Examination of the role of IL-15 in promoting a regulatory response by CD8 T cells would 
contribute to understanding the role of this cytokine in the progression of EAE, whether it 
acts to ameliorate or exacerbate disease. 
We found that CNS-infiltrating T cells are potentially responsive to IL-15, 
expressing CD122 (IL-2/15Rβ) in addition to IL-15Rα. While signaling is mediated 
through CD122 and the common gamma chain, there seems to be a role for IL-15Rα 
expressed on T cells as well. The unique presence of IL-15Rα-expressing T cells in the 
CNS and not in the draining lymph nodes and spleen (Figs. 15&16) is indicative of their 
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activation state and responsiveness to IL-15. One study detected IL-15Rα expression on 
dividing T cells, and demonstrated that IL-15 was necessary for stimulating cell division in 
vivo (Li et al., 2001). Furthermore, in a transgenic mouse model (for leukemia) 
constitutively expressing IL-15, it was found that aggressive uncontrolled expansion of 
CD8 T cells was dependent on IL-15Rα expression; non-activated T cells were not found 
to express IL-15Rα (Sato et al., 2011). Thus the presence of IL-15 in the CNS would be 
responsible for the activation and proliferation of CNS-infiltrating CD8 and, to a lesser 
extent, CD4 T cells expressing IL-15Rα. This would also serve to explain the different 
profiles of T cells found in the CNS, and those in the spleen or draining lymph nodes. IL-
15Rα-expressing T cells were only found in the CNS. Not only can IL-15 promote 
activation and infiltration of macrophages and T cells (Gómez-Nicola et al., 2008b), but 
also, once within the CNS, the activation and proliferation of T cells promoted by IL-15 in 
EAE may be restricted to those cells expressing the IL-15Rα as already indicated in other 
models (Li et al., 2001; Sato et al., 2011). Further studies will need to be carried out, 
examining more mice at the onset and peak of disease, to determine the role of IL-15 and 
possibly the role of IL-15Rα during the course of disease. 
The implicated importance of both IL-15 and IL-15Rα indicates that further 
characterization of the role of IL-15Rα expressed by CNS-infiltrating CD8 T cells would 
be of great interest in addition to determining the effect of IL-15 on these cells and in 
modulating disease course. As IL-15 has a great influence on memory CD8 T cells, it 
would be interesting to characterize specific cell subsets of CD8 T cells, to differentiate 
between CD8 effector and central memory cells. Future studies could include identifying 
subsets of T cells expressing IL-15Rα, whether it is limited to one subset or if it is 
ubiquitously expressed among the T cell population; this would involve examining cells 
infiltrating the CNS, compared to cells found in the spleen and draining lymph node. In 
addition, the role of IL-15 in non-specific (i.e. antigen independent) activation and 
proliferation of T cells isolated from organs could be determined, and compared to specific 
re-activation of immune cells by corresponding peptides (i.e. immune cells isolated from 
B6 mice would be reactivated by MOG35-55). The proportions of CD8 and CD4 T cells as 
well as the proportions of each expressing IL-15Rα determined and compared.  
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We have preliminary data indicating that cells from the spleen and draining lymph 
nodes are potentially responsive to reactivation with peptide, in that they produce IFNγ. It 
would be of great interest to determine whether the presence or absence of IL-15 can 
influence the response of T cells to peptide restimulation, and whether there is a 
relationship with the proportion of responsive T cells expressing IL-15Rα.  
To be able to determine the role of IL-15 in influencing the course of EAE, it is 
useful to use animals deficient in the molecule of interest. However, as previously noted, 
the immune system and response of IL-15 knockout mice are skewed (the numbers of NK 
and CD8 T cells are substantially decreased (Kennedy et al., 2000)) and thus inducing 
active EAE will not give reliable results regarding the role of IL-15. Studies using IL-15 
knockout mice have been done, but it must be noted that in these studies, the severity of 
disease was not very great. In one study, the highest score observed in wild type mice was 
around 1.6; in the knockout, scores averaged at 2.4 (Gomez-Nicola et al., 2010). In 
another, wild type mice with active EAE hovered at around 1.0, while the knockout 
reached scores of 2.5; administering IL-15 reduced the severity of EAE, with mice 
showing scores of around 2.0 (Wu et al., 2010). While it seems IL-15 has a beneficial 
effect on the course of EAE, there already is a difference in the induction of disease due to 
immune system differences between wild type and IL-15 knockout mice, thus creating a 
bias to the results observed. This potential bias may be overcome by adoptive transfer of 
immune cells into knockout mice, and inducing passive EAE.  
In addition to the role of IL-15, the effect of IL-15 on specific immune cell subsets 
can also be examined. For example, CD8 or CD4 T cells reactivated in vitro may be 
transferred, and the effect of IL-15 on disease mediated by each of these cell types 
determined. The role of IL-15 on immune cells found in the CNS, spleen and draining 
lymph nodes should perhaps be determined prior to adoptive transfer. Considering the 
previously described role for IL-15Rα in T cell responsiveness to IL-15 and if the addition 
of IL-15 promotes the re-activation of a specific subset of immune cells, then it may be 
these cells which need to be transferred to determine the effects of IL-15 in the course of 
EAE. Results thus far would indicate that CNS-infiltrating T cells are more likely to 
respond to the addition of IL-15, and thus might be preferable for transfer. However, the 
numbers of immune cells isolated from the CNS of sick animals is variable, and perhaps 
too little to efficiently induce passive EAE. To examine the effects of IL-15 provided by 
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cells of the CNS vs. peripheral cells, mice deficient in IL-15 in either the CNS or in the 
peripheral cells may be used.   
Lastly, further experiments can be extended to immunohistochemistry. We have 
frozen sections of CNS tissue, in addition to spleen and liver, from mice at various stages 
of disease. IL-15 has proven thus far to be difficult to detect in murine brain sections, but 
this is currently being optimized in our lab. We are planning to examine the expression and 
presence of T cells, B cells, macrophages/microglia, and astrocytes in relation to IL-15. 
We will also try to correlate the spatial relationship of cells with each other, to see what 
cell types are interacting with each other, as well as examine the pathogenesis of disease, 
including demyelination and axonal loss. 
The presence of IL-15 expressed on immune cells found in the CNS of mice with 
active EAE, as well as the specific expression of IL-15Rα on T cells also found in the CNS 
in addition to CD122 all indicate that IL-15 likely has a role in the course of disease. 
However, further experiments are required to further and more specifically characterize the 
CNS-infiltrating immune cells expressing IL-15, and to determine the role and influence of 
IL-15 in modulating the disease course. For instance, using a blocking antibody, IL-15 can 
be blocked in the periphery, which would demonstrate the effects and role of peripheral IL-
15 as opposed to the IL-15 to be found within the CNS – whether peripheral IL-15 
enhances immune cell infiltration into the CNS, whether the extent to which it activates 
cells in the periphery influences the ultimate effects observed within the CNS, or whether, 
indeed, it has a role in promoting the development of regulatory CD8 T cells. The presence 
of CD122+ CD8 T cells, potentially responsive to IL-15, has already been shown to have a 
regulatory role in EAE (Lee et al., 2008), supporting a positive effect of IL-15 on disease 
pathogenesis through promotion of regulatory T cell development. 
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CONCLUSION 
IL-15 is a cytokine that has already been implicated in various autoimmune 
diseases (Davey et al., 2005; DePaolo et al., 2011; McInnes and Gracie, 2004; Thurkow et 
al., 1997). Its role in such cases are most likely mediated through CD8 T cells, as it is these 
cells that IL-15 affects the most. Furthermore, as CD8 T cells are capable of directly 
causing damage to cells, non-specific activation (i.e. Ag-independent) of these cells could 
lead to grave consequences, such as the activation of self-reactive cells (Ramanathan et al., 
2011). Self-reactive cells that are aberrantly activated have the potential to recognize self-
Ag and cause damage, resulting in disease.  
While IL-15 is detected in MS patients (Saikali et al., 2010; Schneider et al., in 
press; Vaknin-Dembinsky et al., 2008), its contribution to disease pathogenesis remains 
unknown; whether it plays a role in the initiation of disease, in relapses, or in recovery 
needs to be identified. Using animal models to mimic aspects of MS have proved to be 
useful thus far, and will continue to be so. Characterizing the expression profile of IL-15 
during disease course of EAE in the mouse model allows us to take the first steps towards 
understanding the contribution and role of IL-15 in disease pathogenesis in EAE, which 
can then be extrapolated back to MS. Of course, it is hoped that developing an 
understanding of the role of this, or any, molecule in disease pathogenesis will lead to the 
identification of new therapeutic targets. There is great potential for IL-15 as a target in 
MS; it has already been demonstrated to be an effective target in the treatment of 
rheumatoid arthritis and psoriasis. Understanding when IL-15 plays a significant role in 
disease pathogenesis will hopefully allow the development of additional treatments for 
MS.  
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